{"matching_results": 26637, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1733, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1511}, {"key": "negative", "matching_results": 207}, {"key": "neutral", "matching_results": 15}]}]}, {"key": "tickerreport.com", "matching_results": 985, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 880}, {"key": "negative", "matching_results": 103}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "watchlistnews.com", "matching_results": 959, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 862}, {"key": "negative", "matching_results": 96}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "wkrb13.com", "matching_results": 947, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 848}, {"key": "negative", "matching_results": 99}]}]}, {"key": "dailypolitical.com", "matching_results": 864, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 773}, {"key": "negative", "matching_results": 89}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "freelancer.com.co", "matching_results": 682, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 614}, {"key": "negative", "matching_results": 58}, {"key": "neutral", "matching_results": 10}]}]}, {"key": "thelincolnianonline.com", "matching_results": 624, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 552}, {"key": "negative", "matching_results": 71}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 492, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 445}, {"key": "negative", "matching_results": 47}]}]}, {"key": "theolympiareport.com", "matching_results": 383, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 333}, {"key": "negative", "matching_results": 50}]}]}, {"key": "ecommerce.matrix-e.com", "matching_results": 350, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 282}, {"key": "negative", "matching_results": 68}]}]}]}], "results": [{"id": "2T1osXBr8zYAcyRHMTKf7CEqZWllSPcHORoMCiM-fnUk8GjwufNZlP4RRGBRqIv-", "result_metadata": {"score": 37.296684}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oral Solid Dosage Pharmaceutical Formulation Market", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.5%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Pharmaceutical formulation", "relevance": 0.895888, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_formulation"}], "categories": [{"score": 0.763792, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.36321, "label": "/science/weather"}, {"score": 0.351575, "label": "/health and fitness"}], "relations": [], "keywords": [{"text": "Dosage Pharmaceutical Formulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.996446}, {"text": "Forecast Period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466237}]}, "crawl_date": "2018-11-03T00:55:34Z", "url": "http://www.sbwire.com/press-releases/global-oral-solid-dosage-pharmaceutical-formulation-market-to-register-65-cagr-during-the-forecast-period-2017-to-2027-1078630.htm", "host": "sbwire.com", "text": "Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "main_image_url": "http://media.releasewire.com/photos/show/?id=79336", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-03T01:00:00Z", "enriched_text": {"entities": [{"count": 18, "sentiment": {"score": 0.167951, "label": "positive"}, "text": "Oral Solid Dosage Pharmaceutical Formulation Market", "relevance": 0.912916, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.586847, "label": "positive"}, "text": "Oral Solid Dosage Pharmaceutical Formulation", "relevance": 0.271743, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.443029, "label": "positive"}, "text": "Oral Solid Dosage Pharmaceutical Formulation North America", "relevance": 0.23674, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.148645, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 6, "sentiment": {"score": 0.716209, "label": "positive"}, "text": "Latin America", "relevance": 0.145456, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 3, "sentiment": {"score": 0.0789357, "label": "positive"}, "text": "North America", "relevance": 0.13335, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "FMI", "relevance": 0.10323, "type": "Organization", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}, {"count": 3, "sentiment": {"score": -0.625144, "label": "negative"}, "text": "APEJ", "relevance": 0.101995, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": -0.548104, "label": "negative"}, "text": "Japan", "relevance": 0.0923597, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": 0.413786, "label": "positive"}, "text": "Valley Cottage", "relevance": 0.0892536, "type": "Facility", "disambiguation": {"subtype": [], "name": "Valley Cottage (Georgetown, Maryland)", "dbpedia_resource": "http://dbpedia.org/resource/Valley_Cottage_(Georgetown,_Maryland)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NY", "relevance": 0.0838084, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Otsuka Pharmaceutical Co.", "relevance": 0.0832849, "type": "Company", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.0771715, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": -0.530235, "label": "negative"}, "text": "diabetes", "relevance": 0.0756081, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.074797, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.522212, "label": "negative"}, "text": "Hospital pharmacy", "relevance": 0.0739263, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Europe", "relevance": 0.0724435, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.0704984, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Media Relations Contact", "relevance": 0.0703412, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilead Sciences", "relevance": 0.0691734, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Gilead Sciences", "dbpedia_resource": "http://dbpedia.org/resource/Gilead_Sciences"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.0680279, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.066755, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.0661334, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.0652689, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.0649003, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.206781, "label": "negative"}, "text": "Bayer AG", "relevance": 0.0647773, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Inc", "relevance": 0.0640154, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen Inc.", "relevance": 0.0625422, "type": "Company", "disambiguation": {"subtype": [], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc.", "relevance": 0.0618236, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.249578, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.0617807, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0613902, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgene Corporation", "relevance": 0.0610679, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.0607956, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0.571628, "label": "positive"}, "text": "Korea", "relevance": 0.0604887, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "Country"], "name": "Korea", "dbpedia_resource": "http://dbpedia.org/resource/Korea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceticals", "relevance": 0.0575151, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.0541449, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hoffman-La-Roche Ltd.", "relevance": 0.0540865, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc.", "relevance": 0.0534758, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.0516897, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.571628, "label": "positive"}, "text": "India", "relevance": 0.0501715, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.5%", "relevance": 0.0501715, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0501715, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.1%", "relevance": 0.0501715, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.4%", "relevance": 0.0501715, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7.4%", "relevance": 0.0501715, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.2%", "relevance": 0.0501715, "type": "Quantity"}], "sentiment": {"document": {"score": 0.283021, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Fastest Growing Market", "keywords": [{"text": "Fastest Growing Market"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "sentence": "Global Oral Solid Dosage Pharmaceutical Formulation Market to Register 6.5% CAGR During the Forecast Period 2017 to 2027 Latin America to be Fastest Growing Market for Oral Solid Dosage Pharmaceutical Formulation", "object": {"text": "for Oral Solid Dosage Pharmaceutical Formulation", "keywords": [{"text": "Dosage Pharmaceutical Formulation"}, {"text": "Oral"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "to be", "normalized": "to be"}}, {"subject": {"text": "Valley Cottage, NY -- ( SBWIRE ) -- 11/02/2018 --", "keywords": [{"text": "Valley Cottage"}, {"text": "SBWIRE"}, {"text": "NY"}], "entities": [{"type": "Facility", "text": "Valley Cottage", "disambiguation": {"subtype": [], "name": "Valley Cottage (Georgetown, Maryland)", "dbpedia_resource": "http://dbpedia.org/resource/Valley_Cottage_(Georgetown,_Maryland)"}}, {"type": "Location", "text": "NY", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}]}, "sentence": " Valley Cottage, NY -- ( SBWIRE ) -- 11/02/2018 -- Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential.", "object": {"text": "pipeline productivity", "keywords": [{"text": "pipeline productivity"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "oral solid dosage forms", "keywords": [{"text": "oral solid dosage"}]}, "sentence": " Valley Cottage, NY -- ( SBWIRE ) -- 11/02/2018 -- Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential.", "object": {"text": "substantial opportunity", "keywords": [{"text": "substantial opportunity"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "hold", "normalized": "hold"}}, {"subject": {"text": "Manufacturers", "keywords": [{"text": "Manufacturers"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations", "keywords": [{"text": "rapid release formulations"}, {"text": "new drug formulations"}, {"text": "various life cycle"}, {"text": "management patent strategies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Manufacturers", "keywords": [{"text": "Manufacturers"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "various life cycle management patent strategies", "keywords": [{"text": "various life cycle"}, {"text": "management patent strategies"}]}, "action": {"verb": {"text": "employ", "tense": "present"}, "text": "are employing", "normalized": "be employ"}}, {"subject": {"text": "obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations", "keywords": [{"text": "rapid release formulations"}, {"text": "new drug formulations"}, {"text": "isomers"}, {"text": "prodrugs"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "cycle management patent strategies", "keywords": [{"text": "cycle management patent"}, {"text": "strategies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "patents", "keywords": [{"text": "patents"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "on isomers", "keywords": [{"text": "isomers"}]}, "action": {"verb": {"text": "obtain", "tense": "present"}, "text": "include obtaining", "normalized": "include obtain"}}, {"subject": {"text": "Future Market Insights (FMI), in its report,", "keywords": [{"text": "Future Market Insights"}, {"text": "FMI"}, {"text": "report"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "sentence": " Future Market Insights (FMI), in its report, projects the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027.", "object": {"text": "the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "forecast period"}, {"text": "market"}, {"text": "CAGR"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}, {"type": "Quantity", "text": "6.5"}]}, "action": {"verb": {"text": "project", "tense": "present"}, "text": "projects", "normalized": "project"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "$ 500,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 500,000"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "will reach", "normalized": "will reach"}}, {"subject": {"text": "2027"}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "further estimated to surpass US$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 900,000"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "to surpass US"}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 900,000"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "US"}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "is further estimated to surpass", "normalized": "be far estimate to surpass"}}, {"subject": {"text": "by Asia Pacific Excluding Japan (APEJ) and Western Europe", "keywords": [{"text": "Asia Pacific Excluding"}, {"text": "Western Europe"}, {"text": "Japan"}, {"text": "APEJ"}], "entities": [{"type": "Organization", "text": "Asia Pacific"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2782 North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "object": {"text": "oral solid dosage pharmaceutical formulation,", "keywords": [{"text": "dosage pharmaceutical formulation"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Revenue from the market in North America", "keywords": [{"text": "Revenue"}, {"text": "North America"}, {"text": "market"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Revenue from the market in North America is expected to surpass US$ 300,000 Mn by 2027-end.", "object": {"text": "$ 300,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 300,000"}]}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "is expected to surpass", "normalized": "be expect to surpass"}}, {"subject": {"text": "APEJ", "keywords": [{"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "APEJ", "keywords": [{"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027.", "object": {"text": "revenue worth US$ 294,750.4 Mn in the market", "keywords": [{"text": "revenue worth"}, {"text": "Mn"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is projected to reach", "normalized": "be project to reach"}}, {"subject": {"text": "Latin America", "keywords": [{"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Latin America is expected to be the fastest growth region in the market, expanding at 9.2% CAGR through 2027.", "object": {"text": "the fastest growth region", "keywords": [{"text": "fastest growth region"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}]}, "sentence": " In contrast, Japan will witness a sluggish growth in the market.", "object": {"text": "a sluggish growth in the market", "keywords": [{"text": "sluggish growth"}, {"text": "market"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "will witness", "normalized": "will witness"}}, {"subject": {"text": "US"}, "sentence": " By dosage form, tablets will continue to remain preferred in the market, with sales estimated to surpass US$ 500,000 Mn by 2027-end.", "object": {"text": "$ 500,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 500,000"}]}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "estimated to surpass", "normalized": "estimate to surpass"}}, {"subject": {"text": "Sales of tablets", "keywords": [{"text": "tablets"}, {"text": "Sales"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Sales of tablets", "keywords": [{"text": "tablets"}, {"text": "Sales"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "are anticipated to exhibit", "normalized": "be anticipate to exhibit"}}, {"subject": {"text": "the highest CAGR in the market", "keywords": [{"text": "highest CAGR"}, {"text": "market"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "by capsules", "keywords": [{"text": "capsules"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Capsules", "keywords": [{"text": "Capsules"}]}, "sentence": " Capsules are expected to be the second most lucrative dosage form in the market, expanding at 6.1% CAGR through 2027.", "object": {"text": "the second most lucrative dosage form in the market", "keywords": [{"text": "lucrative dosage form"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Immediate release", "keywords": [{"text": "Immediate release"}]}, "sentence": " Immediate release is expected to generate revenue over US$ 400,000 Mn by 2027-end.", "object": {"text": "revenue over US$ 400,000 Mn by 2027-end", "keywords": [{"text": "revenue"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "generate", "tense": "future"}, "text": "is expected to generate", "normalized": "be expect to generate"}}, {"subject": {"text": "7.4% CAGR", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "7.4"}]}, "sentence": " Controlled release under extended release segment, is expected to register 7.4% CAGR through 2027.", "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "Retail pharmacy", "keywords": [{"text": "Retail pharmacy"}]}, "sentence": " Retail pharmacy is expected to be the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end.", "object": {"text": "the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "largest end-user"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Retail pharmacy", "keywords": [{"text": "Retail pharmacy"}]}, "sentence": " Retail pharmacy is expected to exhibit highest CAGR in the market through 2027.", "object": {"text": "highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "Hospital pharmacy", "keywords": [{"text": "Hospital pharmacy"}], "entities": [{"type": "Facility", "text": "Hospital pharmacy"}]}, "sentence": " In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.", "object": {"text": "lowest CAGR", "keywords": [{"text": "lowest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "it"}, "sentence": " In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.", "object": {"text": "as second largest end-user", "keywords": [{"text": "largest end-user"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "Presence of MNCs", "keywords": [{"text": "Presence"}, {"text": "MNCs"}]}, "sentence": " Increasing Presence of MNCs to Drive Market Growth in Latin America Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "object": {"text": "to Drive Market Growth in Latin America Latin America", "keywords": [{"text": "Drive Market Growth"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "Increasing", "tense": "present"}, "text": "Increasing", "normalized": "Increasing"}}, {"subject": {"text": "Increasing Presence of MNCs to Drive Market Growth in Latin America Latin America", "keywords": [{"text": "Drive Market Growth"}, {"text": "Latin America"}, {"text": "Presence"}, {"text": "MNCs"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Increasing Presence of MNCs to Drive Market Growth in Latin America Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "object": {"text": "emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources", "keywords": [{"text": "oral solid dosage"}, {"text": "manufacturing hub"}, {"text": "low-cost resources"}, {"text": "availability"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Multinational companies", "keywords": [{"text": "Multinational companies"}]}, "sentence": " Multinational companies are focusing on expanding their presence in this region.", "object": {"text": "focusing on expanding their presence in this region", "keywords": [{"text": "presence"}, {"text": "region"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Multinational companies", "keywords": [{"text": "Multinational companies"}]}, "sentence": " Multinational companies are focusing on expanding their presence in this region.", "object": {"text": "their presence", "keywords": [{"text": "presence"}]}, "action": {"verb": {"text": "expand", "tense": "future"}, "text": "expanding", "normalized": "expand"}}, {"subject": {"text": "These factors", "keywords": [{"text": "factors"}]}, "sentence": " These factors are expected to propel market growth in Latin America.", "object": {"text": "market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "are expected to propel", "normalized": "be expect to propel"}}, {"subject": {"text": "They"}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region", "keywords": [{"text": "commonly used pharmaceuticals"}, {"text": "various disease conditions"}, {"text": "North America"}, {"text": "turn"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "pharmaceuticals", "keywords": [{"text": "pharmaceuticals"}]}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "for treating various disease conditions in North America, which in turn is driving growth of the market in this region", "keywords": [{"text": "various disease conditions"}, {"text": "North America"}, {"text": "turn"}, {"text": "growth"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "growth of the market in this region", "keywords": [{"text": "growth"}, {"text": "market"}, {"text": "region"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "is driving", "normalized": "be drive"}}, {"subject": {"text": "Growing effluent consumers in APEJ countries such as China, India and Korea", "keywords": [{"text": "effluent consumers"}, {"text": "APEJ countries"}, {"text": "Korea"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Korea", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "Country"], "name": "Korea", "dbpedia_resource": "http://dbpedia.org/resource/Korea"}}]}, "sentence": " Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "object": {"text": "growth of the oral solid dosage pharmaceutical formulation market in this region", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "growth"}, {"text": "market"}, {"text": "region"}]}, "action": {"verb": {"text": "boost", "tense": "present"}, "text": "are boosting", "normalized": "be boost"}}, {"subject": {"text": "Consumers here", "keywords": [{"text": "Consumers"}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity", "keywords": [{"text": "western lifestyle-related diseases"}, {"text": "wealthy-life-fast-paced western lifestyle"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Consumers here", "keywords": [{"text": "Consumers"}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "wealthy-life-fast-paced western lifestyle", "keywords": [{"text": "wealthy-life-fast-paced western lifestyle"}]}, "action": {"verb": {"text": "adopt", "tense": "present"}, "text": "are adopting", "normalized": "be adopt"}}, {"subject": {"text": "diabetes, cancer, and obesity", "keywords": [{"text": "obesity"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "western lifestyle-related diseases", "keywords": [{"text": "western lifestyle-related diseases"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "This"}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "them"}, "action": {"verb": {"text": "compel", "tense": "present"}, "text": "compels", "normalized": "compel"}}, {"subject": {"text": "them"}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seeking", "normalized": "seek"}}, {"subject": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "expected to fuel market growth in APEJ", "keywords": [{"text": "market growth"}, {"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "market growth in APEJ", "keywords": [{"text": "market growth"}, {"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is expected to fuel", "normalized": "be expect to fuel"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "object": {"text": "productivity of Asian manufacturers and containment issues", "keywords": [{"text": "containment issues"}, {"text": "productivity"}, {"text": "Asian manufacturers"}]}, "action": {"verb": {"text": "decrease", "tense": "present"}, "text": "decreasing", "normalized": "decrease"}}, {"subject": {"text": "low R&D expenditure", "keywords": [{"text": "low R&D expenditure"}]}, "sentence": " However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "object": {"text": "with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ", "keywords": [{"text": "USFDA compliance"}, {"text": "challenges"}, {"text": "growth"}, {"text": "market"}], "entities": [{"type": "JobTitle", "text": "Oral Solid Dosage Pharmaceutical Formulation Market"}, {"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players", "keywords": [{"text": "https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players"}]}, "sentence": " Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc", "keywords": [{"text": "Boehringer Ingelheim GmbH"}, {"text": "Bristol-Myers Squibb Company"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "AstraZeneca Plc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Gilead Sciences", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Gilead Sciences", "dbpedia_resource": "http://dbpedia.org/resource/Gilead_Sciences"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Hoffman-La-Roche Ltd."}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Biogen Inc.", "disambiguation": {"subtype": ["Company"], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Teva Pharmaceticals"}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Company", "text": "Otsuka Pharmaceutical Co.", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"type": "Company", "text": "Ltd."}, {"type": "Company", "text": "Shire Plc."}, {"type": "Company", "text": "Celgene Corporation", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"type": "Company", "text": "Astellas Pharma Inc"}]}, "sentence": " Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "object": {"text": "https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report", "keywords": [{"text": "https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players"}, {"text": "FMI"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.964875, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "North America", "relevance": 0.929778, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacy", "relevance": 0.904686, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmaceutical formulation", "relevance": 0.814476, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_formulation"}, {"text": "Bristol-Myers Squibb", "relevance": 0.751843, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "United States", "relevance": 0.635276, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Pharmaceutical companies of Japan", "relevance": 0.594, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_Japan"}, {"text": "Boehringer Ingelheim", "relevance": 0.57626, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Multinational companies", "relevance": 0.565812, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Americas", "relevance": 0.565275, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Americas", "relevance": 0.53546, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Biotechnology companies", "relevance": 0.526285, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.516936, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Latin America", "relevance": 0.487567, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Novartis", "relevance": 0.484338, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Pharmaceutical industry", "relevance": 0.475264, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "AstraZeneca", "relevance": 0.474714, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Ingelheim am Rhein", "relevance": 0.474357, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "Pfizer", "relevance": 0.474216, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Dosage forms", "relevance": 0.434978, "dbpedia_resource": "http://dbpedia.org/resource/Dosage_forms"}, {"text": "Indigenous peoples of the Americas", "relevance": 0.423865, "dbpedia_resource": "http://dbpedia.org/resource/Indigenous_peoples_of_the_Americas"}], "categories": [{"score": 0.714474, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.452827, "label": "/business and industrial/manufacturing"}, {"score": 0.325643, "label": "/health and fitness"}], "relations": [{"type": "locatedAt", "sentence": "Global Oral Solid Dosage Pharmaceutical Formulation Market to Register 6.5% CAGR During the Forecast Period 2017 to 2027 Latin America to be Fastest Growing Market for Oral Solid Dosage Pharmaceutical Formulation Valley Cottage, NY -- ( SBWIRE ) -- 11/02/2018 -- Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential.", "score": 0.728072, "arguments": [{"text": "Market for Oral Solid Dosage Pharmaceutical Formulation\nValley Cottage", "location": [157, 227], "entities": [{"type": "Organization", "text": "Market for Oral Solid Dosage Pharmaceutical Formulation\nValley Cottage"}]}, {"text": "NY", "location": [229, 231], "entities": [{"type": "GeopoliticalEntity", "text": "NY"}]}]}, {"type": "hasAttribute", "sentence": "Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "score": 0.669607, "arguments": [{"text": "them", "location": [3674, 3678], "entities": [{"type": "Person", "text": "their"}]}, {"text": "diseases", "location": [3715, 3723], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "basedIn", "sentence": "However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "score": 0.771607, "arguments": [{"text": "manufacturers", "location": [3936, 3949], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Asian", "location": [3930, 3935], "entities": [{"type": "GeopoliticalEntity", "text": "Asian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. Media Relations Contact", "score": 0.784587, "arguments": [{"text": "Methodology @", "location": [4123, 4136], "entities": [{"type": "Organization", "text": "Methodology @", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [4116, 4122], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "employedBy", "sentence": "Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. Media Relations Contact", "score": 0.609883, "arguments": [{"text": "players", "location": [4197, 4204], "entities": [{"type": "Person", "text": "players"}]}, {"text": "Key", "location": [4193, 4196], "entities": [{"type": "Organization", "text": "Key", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. Media Relations Contact", "score": 0.515097, "arguments": [{"text": "players", "location": [4197, 4204], "entities": [{"type": "Person", "text": "players"}]}, {"text": "FMI", "location": [4219, 4222], "entities": [{"type": "GeopoliticalEntity", "text": "FMI"}]}]}, {"type": "agentOf", "sentence": "Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. Media Relations Contact", "score": 0.742802, "arguments": [{"text": "FMI", "location": [4219, 4222], "entities": [{"type": "GeopoliticalEntity", "text": "FMI"}]}, {"text": "report", "location": [4225, 4231], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "employedBy", "sentence": "Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. Media Relations Contact", "score": 0.396276, "arguments": [{"text": "Hoffman", "location": [4412, 4419], "entities": [{"type": "Person", "text": "Hoffman"}]}, {"text": "Roche Ltd.", "location": [4423, 4433], "entities": [{"type": "Organization", "text": "Roche Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2782 North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "score": 0.96908, "arguments": [{"text": "Asia Pacific Excluding Japan", "location": [1312, 1340], "entities": [{"type": "Organization", "text": "Asia Pacific Excluding Japan", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "APEJ", "location": [1342, 1346], "entities": [{"type": "Ticker", "text": "APEJ"}]}]}, {"type": "locatedAt", "sentence": "To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2782 North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "score": 0.891566, "arguments": [{"text": "Western", "location": [1352, 1359], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [1360, 1366], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Increasing Presence of MNCs to Drive Market Growth in Latin America Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "score": 0.828117, "arguments": [{"text": "Market Growth", "location": [2845, 2858], "entities": [{"type": "Organization", "text": "Global Oral Solid Dosage Pharmaceutical Formulation Market"}]}, {"text": "Latin America", "location": [2862, 2875], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Increasing Presence of MNCs to Drive Market Growth in Latin America Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "score": 0.917253, "arguments": [{"text": "Latin America", "location": [2876, 2889], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Latin America", "location": [2862, 2875], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.620649, "arguments": [{"text": "consumers", "location": [3441, 3450], "entities": [{"type": "Person", "text": "Consumers"}]}, {"text": "countries", "location": [3459, 3468], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.915942, "arguments": [{"text": "countries", "location": [3459, 3468], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "APEJ", "location": [3454, 3458], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}]}, {"type": "partOfMany", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.233982, "arguments": [{"text": "China", "location": [3477, 3482], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3459, 3468], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.353547, "arguments": [{"text": "India", "location": [3484, 3489], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3459, 3468], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "oral solid dosage", "sentiment": {"score": 0.621171, "label": "positive"}, "relevance": 0.972222}, {"text": "dosage pharmaceutical formulation", "sentiment": {"score": 0.566051, "label": "positive"}, "relevance": 0.792923}, {"text": "pharmaceutical formulation market", "sentiment": {"score": 0.593194, "label": "positive"}, "relevance": 0.590799}, {"text": "Solid Dosage Pharmaceutical", "sentiment": {"score": 0.634787, "label": "positive"}, "relevance": 0.533663}, {"text": "Latin America", "sentiment": {"score": 0.716209, "label": "positive"}, "relevance": 0.475004}, {"text": "dosage forms", "sentiment": {"score": 0.737942, "label": "positive"}, "relevance": 0.469949}, {"text": "solid dosage forms", "sentiment": {"score": 0.786532, "label": "positive"}, "relevance": 0.464002}, {"text": "North America", "sentiment": {"score": 0.157871, "label": "positive"}, "relevance": 0.435157}, {"text": "forecast period", "sentiment": {"score": 0.40361, "label": "positive"}, "relevance": 0.419104}, {"text": "Global Oral Solid", "sentiment": {"score": 0.730666, "label": "positive"}, "relevance": 0.412919}, {"text": "lucrative dosage form", "sentiment": {"score": 0.483963, "label": "positive"}, "relevance": 0.412783}, {"text": "Remain Largest Market", "sentiment": {"score": 0.443029, "label": "positive"}, "relevance": 0.407268}, {"text": "market growth", "sentiment": {"score": 0.708981, "label": "positive"}, "relevance": 0.405262}, {"text": "Pharmaceutical Formulation North", "sentiment": {"score": 0.443029, "label": "positive"}, "relevance": 0.399911}, {"text": "Future Market Insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39451}, {"text": "Drive Market Growth", "sentiment": {"score": 0.708981, "label": "positive"}, "relevance": 0.393288}, {"text": "immediate release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387119}, {"text": "rapid release formulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380555}, {"text": "fastest growth region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379036}, {"text": "new drug formulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377085}, {"text": "life cycle management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376363}, {"text": "Request Sample Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372225}, {"text": "Otsuka Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37194}, {"text": "highest CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371631}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371299}, {"text": "largest end-user", "sentiment": {"score": 0.150234, "label": "positive"}, "relevance": 0.370868}, {"text": "Asia Pacific Excluding", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370608}, {"text": "Boehringer Ingelheim GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367421}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.365932}, {"text": "low R&D expenditure", "sentiment": {"score": -0.625144, "label": "negative"}, "relevance": 0.364699}, {"text": "western lifestyle-related diseases", "sentiment": {"score": -0.530235, "label": "negative"}, "relevance": 0.364513}, {"text": "https://www.futuremarketinsights.com/askus/rep-gb-2782 Key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363427}, {"text": "various disease conditions", "sentiment": {"score": -0.285157, "label": "negative"}, "relevance": 0.36262}, {"text": "Retail pharmacy", "sentiment": {"score": 0.477289, "label": "positive"}, "relevance": 0.361517}, {"text": "innovative drug treatments", "sentiment": {"score": 0.606077, "label": "positive"}, "relevance": 0.361231}, {"text": "wealthy-life-fast-paced western lifestyle", "sentiment": {"score": 0.340296, "label": "positive"}, "relevance": 0.360517}, {"text": "growth potential", "sentiment": {"score": 0.514618, "label": "positive"}, "relevance": 0.350113}, {"text": "Remain Dominant", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348157}, {"text": "sluggish growth", "sentiment": {"score": -0.548104, "label": "negative"}, "relevance": 0.346963}, {"text": "Mn", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345961}, {"text": "lowest CAGR", "sentiment": {"score": -0.522212, "label": "negative"}, "relevance": 0.342413}, {"text": "patent strategies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341327}, {"text": "product lifecycle", "sentiment": {"score": 0.514618, "label": "positive"}, "relevance": 0.341035}, {"text": "substantial opportunity", "sentiment": {"score": 0.514618, "label": "positive"}, "relevance": 0.340833}, {"text": "Valley Cottage", "sentiment": {"score": 0.413786, "label": "positive"}, "relevance": 0.340464}, {"text": "patent cliff", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340433}, {"text": "release segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340344}, {"text": "release mechanism", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340233}, {"text": "Biogen Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339154}, {"text": "Western Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338871}]}, "extracted_metadata": {"sha1": "42435f983b27df0742a9833aeb6396fd6e5c7011", "filename": "1541206534343.zip-2c42b41681eab52bfda5327ad2efaca1.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market", "https://www.futuremarketinsights.com/askus/rep-gb-2782", "https://www.futuremarketinsights.com/reports/sample/rep-gb-2782"], "title": "Global Oral Solid Dosage Pharmaceutical Formulation Market to Register 6.5% CAGR During the Forecast Period 2017 to 2027", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "wcWLRUzel1htVdGp9JZXmxhCYcwtlSBRKv1Bgp_3a5wFKEfSdTZTWKUrrNORDteG", "result_metadata": {"score": 35.642075}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.395595, "label": "negative"}, "text": "U.S.", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.6%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": -0.395595, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "U.S. Insomnia Market", "keywords": [{"text": "U.S. Insomnia Market"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": "U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets", "object": {"text": "at a CAGR of 4.6% by MarketsandMarkets", "keywords": [{"text": "CAGR"}, {"text": "MarketsandMarkets"}], "entities": [{"type": "Quantity", "text": "4.6"}]}, "action": {"verb": {"text": "Grow", "tense": "future"}, "text": "to Grow", "normalized": "to Grow"}}], "concepts": [{"text": "Arithmetic mean", "relevance": 0.897784, "dbpedia_resource": "http://dbpedia.org/resource/Arithmetic_mean"}], "categories": [{"score": 0.507668, "label": "/real estate/buying and selling homes"}, {"score": 0.496166, "label": "/finance/investing"}, {"score": 0.496166, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "partOf", "sentence": "U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets", "score": 0.982675, "arguments": [{"text": "Insomnia Market Expected", "location": [5, 29], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}, {"text": "U.S.", "location": [0, 4], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "partOf", "sentence": "U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets", "score": 0.659171, "arguments": [{"text": "Grow", "location": [33, 37], "entities": [{"type": "Organization", "text": "Grow"}]}, {"text": "Insomnia Market Expected", "location": [5, 29], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}]}, {"type": "locatedAt", "sentence": "U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets", "score": 0.710921, "arguments": [{"text": "Grow", "location": [33, 37], "entities": [{"type": "Organization", "text": "Grow"}]}, {"text": "CAGR of", "location": [43, 50], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}], "keywords": [{"text": "Insomnia Market Expected", "sentiment": {"score": -0.395595, "label": "negative"}, "relevance": 0.976562}, {"text": "U.S.", "sentiment": {"score": -0.395595, "label": "negative"}, "relevance": 0.220435}, {"text": "CAGR", "sentiment": {"score": -0.395595, "label": "negative"}, "relevance": 0.219267}, {"text": "MarketsandMarkets", "sentiment": {"score": -0.395595, "label": "negative"}, "relevance": 0.218537}]}, "crawl_date": "2018-11-02T16:37:45Z", "url": "http://www.sbwire.com/press-releases/us-insomnia-market-expected-to-grow-at-a-cagr-of-46-by-marketsandmarketstm-1077597.htm", "host": "sbwire.com", "text": "(France), Takeda Pharmaceutical Company Ltd.", "main_image_url": "http://media.releasewire.com/photos/show/?id=147887", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T16:29:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": -0.268291, "label": "negative"}, "text": "insomnia", "relevance": 0.962841, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}, {"count": 11, "sentiment": {"score": -0.409553, "label": "negative"}, "text": "U.S.", "relevance": 0.617431, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 3, "sentiment": {"score": -0.291826, "label": "negative"}, "text": "Melatonin", "relevance": 0.501468, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "MarketsandMarkets", "relevance": 0.38182, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orexin Antagonist", "relevance": 0.380848, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Northbrook", "relevance": 0.364093, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Northbrook, Illinois", "dbpedia_resource": "http://dbpedia.org/resource/Northbrook,_Illinois"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.34859, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IL", "relevance": 0.317977, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zaleplon", "relevance": 0.308478, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Analyst", "relevance": 0.306765, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "benzodiazepine", "relevance": 0.30193, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.2975, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0.674082, "label": "positive"}, "text": "analyst", "relevance": 0.287621, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.280628, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SRT", "relevance": 0.279739, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.238225, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.278097, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pernix Therapeutics Holdings", "relevance": 0.26987, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Meda Consumer Healthcare Inc.", "relevance": 0.266855, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.39785, "label": "negative"}, "text": "Vanda Pharmaceuticals", "relevance": 0.263492, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.252317, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.245041, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.6%", "relevance": 0.245041, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "80%", "relevance": 0.245041, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2021", "relevance": 0.245041, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "70%", "relevance": 0.245041, "type": "Quantity"}], "sentiment": {"document": {"score": 0.105383, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "RSS U.S. Insomnia Market", "keywords": [{"text": "U.S. Insomnia Market"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets\u2122 The U.S. Insomnia Market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.", "object": {"text": "at a CAGR of 4.6% by MarketsandMarkets\u2122 The U.S. Insomnia Market", "keywords": [{"text": "U.S. Insomnia Market"}, {"text": "CAGR"}, {"text": "MarketsandMarkets\u2122"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "4.6"}]}, "action": {"verb": {"text": "Grow", "tense": "future"}, "text": "to Grow", "normalized": "to Grow"}}, {"subject": {"text": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets\u2122 The U.S. Insomnia Market", "keywords": [{"text": "U.S. Insomnia Market"}, {"text": "Insomnia Market Expected"}, {"text": "MarketsandMarkets\u2122 The U.S."}, {"text": "RSS"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "4.6"}]}, "sentence": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets\u2122 The U.S. Insomnia Market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Northbrook, IL -- ( SBWIRE ) -- 11/02/2018 --", "keywords": [{"text": "SBWIRE"}, {"text": "Northbrook"}, {"text": "IL"}], "entities": [{"type": "Location", "text": "Northbrook", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Northbrook, Illinois", "dbpedia_resource": "http://dbpedia.org/resource/Northbrook,_Illinois"}}, {"type": "Location", "text": "IL", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Northbrook, IL -- ( SBWIRE ) -- 11/02/2018 -- According to a new market research report \"U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021\", published by MarketsandMarkets.", "object": {"text": "to a new market research report \"U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021\", published by MarketsandMarkets", "keywords": [{"text": "U.S. Insomnia Market"}, {"text": "new market research"}, {"text": "Valerian Root"}, {"text": "Orexin Antagonist"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Drug", "text": "Zaleplon"}, {"type": "Person", "text": "Orexin Antagonist"}, {"type": "Drug", "text": "Melatonin"}, {"type": "Company", "text": "MarketsandMarkets"}, {"type": "Quantity", "text": "2021\""}]}, "action": {"verb": {"text": "According", "tense": "present"}, "text": "According", "normalized": "According"}}, {"subject": {"text": "Browse 16 market data Tables and 33 Figures spread through 144 Pages and in-depth TOC on \"U.S. Insomnia Market\" http://www.marketsandmarkets.com/Market-Reports/us-insomnia-market-55727597.html This growth", "keywords": [{"text": "U.S. Insomnia Market"}, {"text": "market data Tables"}, {"text": "in-depth TOC"}, {"text": "Browse"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Browse 16 market data Tables and 33 Figures spread through 144 Pages and in-depth TOC on \"U.S. Insomnia Market\" http://www.marketsandmarkets.com/Market-Reports/us-insomnia-market-55727597.html This growth can be attributed to the launch of new drugs for the treatment of insomnia and government support to control rising insomnia cost.", "object": {"text": "to the launch of new drugs for the treatment of insomnia and government support to control rising insomnia cost", "keywords": [{"text": "insomnia cost"}, {"text": "new drugs"}, {"text": "government support"}, {"text": "launch"}], "entities": [{"type": "HealthCondition", "text": "insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}, {"type": "HealthCondition", "text": "insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "attribute", "tense": "future"}, "text": "can be attributed", "normalized": "can be attribute"}}, {"subject": {"text": "generics", "keywords": [{"text": "generics"}]}, "sentence": " However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market.", "object": {"text": "to their low cost and equal efficacy", "keywords": [{"text": "equal efficacy"}, {"text": "low cost"}]}, "action": {"verb": {"text": "attribute", "tense": "past"}, "text": "attributed", "normalized": "attribute"}}, {"subject": {"text": "their low cost and equal efficacy as compared to branded products", "keywords": [{"text": "equal efficacy"}, {"text": "branded products"}, {"text": "low cost"}]}, "sentence": " However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hinder", "tense": "future"}, "text": "may hinder", "normalized": "may hinder"}}, {"subject": {"text": "the U.S. Insomnia Market", "keywords": [{"text": "U.S. Insomnia Market"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Based on the type of treatment, the U.S. Insomnia Market is segmented into non-pharmacological treatment and pharmacological treatment market.", "object": {"text": "segmented into non-pharmacological treatment and pharmacological treatment market", "keywords": [{"text": "pharmacological treatment market"}, {"text": "non-pharmacological treatment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the U.S. Insomnia Market", "keywords": [{"text": "U.S. Insomnia Market"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Based on the type of treatment, the U.S. Insomnia Market is segmented into non-pharmacological treatment and pharmacological treatment market.", "object": {"text": "into non-pharmacological treatment and pharmacological treatment market", "keywords": [{"text": "pharmacological treatment market"}, {"text": "non-pharmacological treatment"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The pharmacological treatment market", "keywords": [{"text": "pharmacological treatment market"}]}, "sentence": " The pharmacological treatment market is further is categorized into prescription sleep aids and over-the-counter sleep aids.", "object": {"text": "further"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The pharmacological treatment market", "keywords": [{"text": "pharmacological treatment market"}]}, "sentence": " The pharmacological treatment market is further is categorized into prescription sleep aids and over-the-counter sleep aids.", "object": {"text": "into prescription sleep aids and over-the-counter sleep aids", "keywords": [{"text": "over-the-counter sleep aids"}, {"text": "prescription sleep aids"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "The OTC sleep aids segment", "keywords": [{"text": "OTC sleep aids"}, {"text": "segment"}]}, "sentence": " The OTC sleep aids segment is expected to grow at the highest CAGR during the forecast period.", "object": {"text": "at the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "the publicity", "keywords": [{"text": "publicity"}]}, "sentence": " Furthermore, the publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid options.", "object": {"text": "the side effects of the prescription sleep aids has", "keywords": [{"text": "prescription sleep aids"}]}, "action": {"verb": {"text": "regard", "tense": "present"}, "text": "regarding", "normalized": "regard"}}, {"subject": {"text": "the publicity regarding the side effects of the prescription sleep aids", "keywords": [{"text": "prescription sleep aids"}, {"text": "publicity"}, {"text": "effects"}]}, "sentence": " Furthermore, the publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid options.", "object": {"text": "the patients", "keywords": [{"text": "patients"}]}, "action": {"verb": {"text": "steer", "tense": "past"}, "text": "has also steered", "normalized": "have also steer"}}, {"subject": {"text": "http://www.marketsandmarkets.com/speaktoanalyst.asp?id=55727597 The prescription sleep aids segment", "keywords": [{"text": "sleep aids segment"}, {"text": "prescription"}]}, "sentence": " Speak to Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=55727597 The prescription sleep aids segment is categorized into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids.", "object": {"text": "categorized into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists", "keywords": [{"text": "melatonin receptor agonists"}, {"text": "orexin antagonists"}, {"text": "benzodiazepines"}, {"text": "non-benzodiazepines"}], "entities": [{"type": "Drug", "text": "Melatonin"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "http://www.marketsandmarkets.com/speaktoanalyst.asp?id=55727597 The prescription sleep aids segment", "keywords": [{"text": "sleep aids segment"}, {"text": "prescription"}]}, "sentence": " Speak to Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=55727597 The prescription sleep aids segment is categorized into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids.", "object": {"text": "into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids", "keywords": [{"text": "melatonin receptor agonists"}, {"text": "prescription sleep aids"}, {"text": "orexin antagonists"}, {"text": "benzodiazepines"}], "entities": [{"type": "Drug", "text": "Melatonin"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "The orexin antagonist sleep aids segment", "keywords": [{"text": "orexin antagonist sleep"}, {"text": "aids segment"}]}, "sentence": " The orexin antagonist sleep aids segment is expected to grow at the highest CAGR during the forecast period due to its greater efficacy than non-benzodiazepine and benzodiazepine drugs.", "object": {"text": "at the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "The OTC sleep aids", "keywords": [{"text": "OTC sleep aids"}]}, "sentence": " The OTC sleep aids is further segmented into antihistamines, melatonin, valerian roots, and other herbal and dietary supplements.", "object": {"text": "further segmented into antihistamines, melatonin, valerian roots", "keywords": [{"text": "valerian roots"}, {"text": "antihistamines"}, {"text": "melatonin"}], "entities": [{"type": "Drug", "text": "Melatonin"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The non-pharmacological treatment market", "keywords": [{"text": "non-pharmacological treatment market"}]}, "sentence": " The non-pharmacological treatment market is categorized into cognitive behavioral therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies.", "object": {"text": "categorized into cognitive behavioral therapy", "keywords": [{"text": "cognitive behavioral therapy"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The non-pharmacological treatment market", "keywords": [{"text": "non-pharmacological treatment market"}]}, "sentence": " The non-pharmacological treatment market is categorized into cognitive behavioral therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies.", "object": {"text": "into cognitive behavioral therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies", "keywords": [{"text": "cognitive behavioral therapy"}, {"text": "alternative therapies"}, {"text": "insomnia"}, {"text": "hypnotherapy"}], "entities": [{"type": "HealthCondition", "text": "insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "exercise/ yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy", "keywords": [{"text": "bright light therapy"}, {"text": "aroma therapy"}, {"text": "biofeedback"}, {"text": "music therapy"}]}, "sentence": " The other alternative therapies include exercise/ yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.", "object": {"text": "The other alternative therapies", "keywords": [{"text": "alternative therapies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Most of these therapies", "keywords": [{"text": "therapies"}]}, "sentence": " Most of these therapies are given in combination with CBTI and hypnotherapies in order to provide better results for insomnia patients.", "object": {"text": "better results", "keywords": [{"text": "better results"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "CBTI", "keywords": [{"text": "CBTI"}]}, "sentence": " CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "object": {"text": "the highly recommended treatment option for insomnia patients", "keywords": [{"text": "highly recommended treatment"}, {"text": "insomnia patients"}, {"text": "option"}], "entities": [{"type": "HealthCondition", "text": "insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "others"}, "sentence": " CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "object": {"text": "doctors to understand", "keywords": [{"text": "doctors"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "others"}, "sentence": " CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "object": {"text": "patient", "keywords": [{"text": "patient"}]}, "action": {"verb": {"text": "cure", "tense": "present"}, "text": "cure", "normalized": "cure"}}, {"subject": {"text": "CBTI", "keywords": [{"text": "CBTI"}]}, "sentence": " CBTI is followed by hypnotherapy, due to its advantage of curing insomnia with its root cause.", "object": {"text": "followed by hypnotherapy", "keywords": [{"text": "hypnotherapy"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.)", "keywords": [{"text": "Meda Consumer Healthcare"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Vanda Pharmaceuticals"}, {"text": "Therapeutics Holdings"}], "entities": [{"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Meda Consumer Healthcare Inc."}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Pernix Therapeutics Holdings"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Country"]}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Vanda Pharmaceuticals"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=55727597 Some of the major players in the U.S. Insomnia Market market include Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.).", "object": {"text": "@ http://www.marketsandmarkets.com/pdfdownload.asp?id=55727597 Some of the major players in the U.S. Insomnia Market market", "keywords": [{"text": "U.S. Insomnia Market"}, {"text": "major players"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "MarketsandMarkets\u2122", "keywords": [{"text": "MarketsandMarkets\u2122"}]}, "sentence": " About MarketsandMarkets\u2122: MarketsandMarkets\u2122 provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.", "object": {"text": "quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues", "keywords": [{"text": "high growth niche"}, {"text": "B2B research"}, {"text": "worldwide companies"}, {"text": "revenues"}], "entities": [{"type": "Quantity", "text": "70"}, {"type": "Quantity", "text": "80"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "70%", "entities": [{"type": "Quantity", "text": "70"}]}, "sentence": " About MarketsandMarkets\u2122: MarketsandMarkets\u2122 provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.", "object": {"text": "to 80% of worldwide companies' revenues", "keywords": [{"text": "revenues"}, {"text": "worldwide companies"}], "entities": [{"type": "Quantity", "text": "80"}]}, "action": {"verb": {"text": "impact", "tense": "future"}, "text": "will impact", "normalized": "will impact"}}, {"subject": {"text": "80% of global Fortune 1000 companies as clients", "keywords": [{"text": "global Fortune"}, {"text": "companies"}, {"text": "clients"}], "entities": [{"type": "Quantity", "text": "80"}]}, "sentence": " Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.", "object": {"text": "servicing 7500 customers worldwide", "keywords": [{"text": "customers"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets\u2122 for their pain", "keywords": [{"text": "industries worldwide approach"}, {"text": "pain"}, {"text": "officers"}, {"text": "MarketsandMarkets\u2122"}]}, "sentence": " Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets\u2122 for their pain points around revenues decisions.", "object": {"text": "around revenues decisions", "keywords": [{"text": "revenues decisions"}]}, "action": {"verb": {"text": "point", "tense": "present"}, "text": "points", "normalized": "point"}}, {"subject": {"text": "Our 850 fulltime analyst and SMEs at MarketsandMarkets\u2122", "keywords": [{"text": "fulltime analyst"}, {"text": "SMEs"}, {"text": "MarketsandMarkets\u2122"}], "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " Our 850 fulltime analyst and SMEs at MarketsandMarkets\u2122 are tracking global high growth markets following the \"Growth Engagement Model \u2013 GEM\".", "object": {"text": "tracking global high growth markets", "keywords": [{"text": "global high growth"}, {"text": "markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Our 850 fulltime analyst and SMEs at MarketsandMarkets\u2122", "keywords": [{"text": "fulltime analyst"}, {"text": "SMEs"}, {"text": "MarketsandMarkets\u2122"}], "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " Our 850 fulltime analyst and SMEs at MarketsandMarkets\u2122 are tracking global high growth markets following the \"Growth Engagement Model \u2013 GEM\".", "object": {"text": "global high growth markets", "keywords": [{"text": "global high growth"}, {"text": "markets"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "are tracking", "normalized": "be track"}}, {"subject": {"text": "global high growth markets", "keywords": [{"text": "global high growth"}, {"text": "markets"}]}, "sentence": " Our 850 fulltime analyst and SMEs at MarketsandMarkets\u2122 are tracking global high growth markets following the \"Growth Engagement Model \u2013 GEM\".", "object": {"text": "the \"Growth Engagement Model \u2013 GEM\"", "keywords": [{"text": "Growth Engagement Model"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "following", "normalized": "follow"}}, {"subject": {"text": "The GEM", "keywords": [{"text": "GEM"}]}, "sentence": " The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write \"Attack, avoid and defend\" strategies, identify sources of incremental revenues for both the company and its competitors.", "object": {"text": "at proactive collaboration", "keywords": [{"text": "proactive collaboration"}]}, "action": {"verb": {"text": "aim", "tense": "present"}, "text": "aims", "normalized": "aim"}}, {"subject": {"text": "the clients", "keywords": [{"text": "clients"}]}, "sentence": " The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write \"Attack, avoid and defend\" strategies, identify sources of incremental revenues for both the company and its competitors.", "object": {"text": "new opportunities", "keywords": [{"text": "new opportunities"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The GEM", "keywords": [{"text": "GEM"}]}, "sentence": " The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write \"Attack, avoid and defend\" strategies, identify sources of incremental revenues for both the company and its competitors.", "object": {"text": "most important customers", "keywords": [{"text": "customers"}]}, "action": {"verb": {"text": "identify", "tense": "present"}, "text": "identify", "normalized": "identify"}}, {"subject": {"text": "most important customers,", "keywords": [{"text": "customers"}]}, "sentence": " The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write \"Attack, avoid and defend\" strategies, identify sources of incremental revenues for both the company and its competitors.", "object": {"text": "Attack", "keywords": [{"text": "Attack"}]}, "action": {"verb": {"text": "write", "tense": "present"}, "text": "write", "normalized": "write"}}, {"subject": {"text": "The GEM", "keywords": [{"text": "GEM"}]}, "sentence": " The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write \"Attack, avoid and defend\" strategies, identify sources of incremental revenues for both the company and its competitors.", "object": {"text": "strategies", "keywords": [{"text": "strategies"}]}, "action": {"verb": {"text": "defend", "tense": "present"}, "text": "avoid and defend", "normalized": "avoid and defend"}}, {"subject": {"text": "MarketsandMarkets\u2122", "keywords": [{"text": "MarketsandMarkets\u2122"}]}, "sentence": " MarketsandMarkets\u2122 now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments.", "object": {"text": "with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators", "keywords": [{"text": "innovators"}, {"text": "MicroQuadrants"}, {"text": "players"}, {"text": "leaders"}]}, "action": {"verb": {"text": "come", "tense": "present"}, "text": "coming", "normalized": "come"}}, {"subject": {"text": "top players", "keywords": [{"text": "players"}]}, "sentence": " MarketsandMarkets\u2122 now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments.", "object": {"text": "across leaders, emerging companies, innovators, strategic players)", "keywords": [{"text": "strategic players"}, {"text": "innovators"}, {"text": "leaders"}, {"text": "companies"}]}, "action": {"verb": {"text": "Positioning", "tense": "present"}, "text": "Positioning", "normalized": "Positioning"}}, {"subject": {"text": "MarketsandMarkets\u2122", "keywords": [{"text": "MarketsandMarkets\u2122"}]}, "sentence": " MarketsandMarkets\u2122 is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.", "object": {"text": "determined to benefit more than 10,000 companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "MarketsandMarkets\u2122", "keywords": [{"text": "MarketsandMarkets\u2122"}]}, "sentence": " MarketsandMarkets\u2122 is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.", "action": {"verb": {"text": "determine", "tense": "past"}, "text": "is determined to benefit", "normalized": "be determine to benefit"}}, {"subject": {"text": "MarketsandMarkets\u2122", "keywords": [{"text": "MarketsandMarkets\u2122"}]}, "sentence": " MarketsandMarkets\u2122 is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.", "object": {"text": "more than 10,000 companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "benefit", "tense": "future"}, "text": "is determined to benefit", "normalized": "be determine to benefit"}}, {"subject": {"text": "them"}, "sentence": " MarketsandMarkets\u2122 is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.", "object": {"text": "their innovations/disruptions", "keywords": [{"text": "innovations/disruptions"}]}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "take", "normalized": "take"}}, {"subject": {"text": "them"}, "sentence": " MarketsandMarkets\u2122 is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.", "object": {"text": "them"}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "MarketsandMarkets's flagship competitive intelligence and market research platform, \"Knowledge Store\"", "keywords": [{"text": "flagship competitive intelligence"}, {"text": "market research platform"}, {"text": "Knowledge Store"}, {"text": "MarketsandMarkets"}], "entities": [{"type": "Company", "text": "MarketsandMarkets"}]}, "sentence": " MarketsandMarkets's flagship competitive intelligence and market research platform, \"Knowledge Store\" connects over 200,000 markets and entire value chains for a deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.", "object": {"text": "over 200,000 markets and entire value chains", "keywords": [{"text": "entire value chains"}, {"text": "markets"}]}, "action": {"verb": {"text": "connect", "tense": "present"}, "text": "connects", "normalized": "connect"}}], "concepts": [{"text": "Therapy", "relevance": 0.984622, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Benzodiazepine", "relevance": 0.930399, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine"}, {"text": "Melatonin", "relevance": 0.705428, "dbpedia_resource": "http://dbpedia.org/resource/Melatonin"}, {"text": "Receptor antagonist", "relevance": 0.684747, "dbpedia_resource": "http://dbpedia.org/resource/Receptor_antagonist"}, {"text": "Zopiclone", "relevance": 0.682386, "dbpedia_resource": "http://dbpedia.org/resource/Zopiclone"}, {"text": "Circadian rhythm", "relevance": 0.676898, "dbpedia_resource": "http://dbpedia.org/resource/Circadian_rhythm"}, {"text": "Narcolepsy", "relevance": 0.66718, "dbpedia_resource": "http://dbpedia.org/resource/Narcolepsy"}, {"text": "Ramelteon", "relevance": 0.654792, "dbpedia_resource": "http://dbpedia.org/resource/Ramelteon"}, {"text": "Delayed sleep phase syndrome", "relevance": 0.644669, "dbpedia_resource": "http://dbpedia.org/resource/Delayed_sleep_phase_syndrome"}, {"text": "Sleep disorder", "relevance": 0.619659, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_disorder"}, {"text": "Agonist", "relevance": 0.618174, "dbpedia_resource": "http://dbpedia.org/resource/Agonist"}, {"text": "Psychotherapy", "relevance": 0.617684, "dbpedia_resource": "http://dbpedia.org/resource/Psychotherapy"}, {"text": "Hypnotic", "relevance": 0.608475, "dbpedia_resource": "http://dbpedia.org/resource/Hypnotic"}, {"text": "Valerian", "relevance": 0.593247, "dbpedia_resource": "http://dbpedia.org/resource/Valerian_(herb)"}, {"text": "Pharmacology", "relevance": 0.591144, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Sleep", "relevance": 0.58466, "dbpedia_resource": "http://dbpedia.org/resource/Sleep"}, {"text": "Cognitive behavioral therapy", "relevance": 0.572822, "dbpedia_resource": "http://dbpedia.org/resource/Cognitive_behavioral_therapy"}, {"text": "Nonbenzodiazepine", "relevance": 0.553039, "dbpedia_resource": "http://dbpedia.org/resource/Nonbenzodiazepine"}, {"text": "Major depressive disorder", "relevance": 0.550316, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Sleep hygiene", "relevance": 0.533936, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_hygiene"}, {"text": "Sedative", "relevance": 0.529968, "dbpedia_resource": "http://dbpedia.org/resource/Sedative"}, {"text": "Seasonal affective disorder", "relevance": 0.519573, "dbpedia_resource": "http://dbpedia.org/resource/Seasonal_affective_disorder"}, {"text": "Jet lag", "relevance": 0.510533, "dbpedia_resource": "http://dbpedia.org/resource/Jet_lag"}, {"text": "Zaleplon", "relevance": 0.49784, "dbpedia_resource": "http://dbpedia.org/resource/Zaleplon"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.486385, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Bipolar disorder", "relevance": 0.479558, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Light therapy", "relevance": 0.47841, "dbpedia_resource": "http://dbpedia.org/resource/Light_therapy"}, {"text": "Over-the-counter drug", "relevance": 0.477948, "dbpedia_resource": "http://dbpedia.org/resource/Over-the-counter_drug"}, {"text": "Phase response curve", "relevance": 0.460958, "dbpedia_resource": "http://dbpedia.org/resource/Phase_response_curve"}, {"text": "Triazolam", "relevance": 0.41648, "dbpedia_resource": "http://dbpedia.org/resource/Triazolam"}, {"text": "Competitor analysis", "relevance": 0.41442, "dbpedia_resource": "http://dbpedia.org/resource/Competitor_analysis"}, {"text": "Treatment of bipolar disorder", "relevance": 0.411499, "dbpedia_resource": "http://dbpedia.org/resource/Treatment_of_bipolar_disorder"}, {"text": "Flunitrazepam", "relevance": 0.404459, "dbpedia_resource": "http://dbpedia.org/resource/Flunitrazepam"}, {"text": "Doxylamine", "relevance": 0.402618, "dbpedia_resource": "http://dbpedia.org/resource/Doxylamine"}, {"text": "Alternative medicine", "relevance": 0.395828, "dbpedia_resource": "http://dbpedia.org/resource/Alternative_medicine"}, {"text": "Valeriana", "relevance": 0.388547, "dbpedia_resource": "http://dbpedia.org/resource/Valeriana"}, {"text": "Sleep medicine", "relevance": 0.382616, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_medicine"}, {"text": "Behaviour therapy", "relevance": 0.379427, "dbpedia_resource": "http://dbpedia.org/resource/Behaviour_therapy"}, {"text": "Orexin", "relevance": 0.379348, "dbpedia_resource": "http://dbpedia.org/resource/Orexin"}, {"text": "Essential oil", "relevance": 0.375828, "dbpedia_resource": "http://dbpedia.org/resource/Essential_oil"}, {"text": "Inverse agonist", "relevance": 0.372471, "dbpedia_resource": "http://dbpedia.org/resource/Inverse_agonist"}, {"text": "Clinical psychology", "relevance": 0.372335, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_psychology"}, {"text": "Ultraviolet", "relevance": 0.371642, "dbpedia_resource": "http://dbpedia.org/resource/Ultraviolet"}, {"text": "Medicine", "relevance": 0.370592, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Chronotype", "relevance": 0.368841, "dbpedia_resource": "http://dbpedia.org/resource/Chronotype"}, {"text": "Christopher Nolan", "relevance": 0.36846, "dbpedia_resource": "http://dbpedia.org/resource/Christopher_Nolan"}], "categories": [{"score": 0.66775, "label": "/health and fitness"}, {"score": 0.62708, "label": "/health and fitness/therapy"}, {"score": 0.228335, "label": "/health and fitness/disorders/sleep disorders"}], "relations": [{"type": "partOf", "sentence": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarketsM The U.S. Insomnia Market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.", "score": 0.979711, "arguments": [{"text": "Insomnia Market Expected", "location": [9, 33], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}, {"text": "U.S.", "location": [4, 8], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Northbrook, IL -- ( SBWIRE ) -- 11/02/2018 -- According to a new market research report \"U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021\", published by MarketsandMarkets.", "score": 0.993721, "arguments": [{"text": "Insomnia Market", "location": [325, 340], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}, {"text": "U.S.", "location": [320, 324], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Browse 16 market data Tables and 33 Figures spread through 144 Pages and in-depth TOC on \"U.S. Insomnia Market\" http://www.marketsandmarkets.com/Market-Reports/us-insomnia-market-55727597.html This growth can be attributed to the launch of new drugs for the treatment of insomnia and government support to control rising insomnia cost.", "score": 0.991867, "arguments": [{"text": "Insomnia Market", "location": [695, 710], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}, {"text": "U.S.", "location": [690, 694], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Based on the type of treatment, the U.S. Insomnia Market is segmented into non-pharmacological treatment and pharmacological treatment market.", "score": 0.994304, "arguments": [{"text": "Insomnia Market", "location": [1178, 1193], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}, {"text": "U.S.", "location": [1173, 1177], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Most of these therapies are given in combination with CBTI and hypnotherapies in order to provide better results for insomnia patients.", "score": 0.831198, "arguments": [{"text": "patients", "location": [2733, 2741], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "insomnia", "location": [2724, 2732], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "hasAttribute", "sentence": "CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "score": 0.847475, "arguments": [{"text": "patients", "location": [2804, 2812], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "insomnia", "location": [2795, 2803], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "employedBy", "sentence": "CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "score": 0.375248, "arguments": [{"text": "patients", "location": [2804, 2812], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "its", "location": [2820, 2823], "entities": [{"type": "Organization", "text": "Non-Pharmacological Therapy"}]}]}, {"type": "partOfMany", "sentence": "Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=55727597 Some of the major players in the U.S. Insomnia Market market include Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.).", "score": 0.739909, "arguments": [{"text": "Some", "location": [3256, 3260], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [3274, 3281], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "employedBy", "sentence": "Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=55727597 Some of the major players in the U.S. Insomnia Market market include Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.).", "score": 0.594678, "arguments": [{"text": "players", "location": [3274, 3281], "entities": [{"type": "Person", "text": "players"}]}, {"text": "Insomnia Market market", "location": [3294, 3316], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}]}, {"type": "basedIn", "sentence": "Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=55727597 Some of the major players in the U.S. Insomnia Market market include Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.).", "score": 0.937541, "arguments": [{"text": "Insomnia Market market", "location": [3294, 3316], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}, {"text": "U.S.", "location": [3289, 3293], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients.", "score": 0.862202, "arguments": [{"text": "companies", "location": [3850, 3859], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Fortune", "location": [3837, 3844], "entities": [{"type": "Organization", "text": "Fortune", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Almost 75,000 top officers across eight industries worldwide approach MarketsandMarketsM for their pain points around revenues decisions.", "score": 0.662387, "arguments": [{"text": "officers", "location": [3890, 3898], "entities": [{"type": "Person", "text": "officers"}]}, {"text": "their", "location": [3965, 3970], "entities": [{"type": "Person", "text": "customers"}]}]}, {"type": "employedBy", "sentence": "Our 850 fulltime analyst and SMEs at MarketsandMarketsM are tracking global high growth markets following the \"Growth Engagement Model - GEM\".", "score": 0.374725, "arguments": [{"text": "SMEs", "location": [4039, 4043], "entities": [{"type": "Person", "text": "SMEs"}]}, {"text": "MarketsandMarkets\u2122", "location": [4047, 4065], "entities": [{"type": "Organization", "text": "MarketsandMarkets\u2122 The U.S. Insomnia Market"}]}]}, {"type": "partOf", "sentence": "The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write \"Attack, avoid and defend\" strategies, identify sources of incremental revenues for both the company and its competitors.", "score": 0.905096, "arguments": [{"text": "competitors", "location": [4391, 4402], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "its", "location": [4387, 4390], "entities": [{"type": "Organization", "text": "GEM"}]}]}, {"type": "partOfMany", "sentence": "MarketsandMarketsM now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments.", "score": 0.666223, "arguments": [{"text": "players", "location": [4480, 4487], "entities": [{"type": "Person", "text": "players"}]}, {"text": "leaders", "location": [4495, 4502], "entities": [{"type": "Person", "text": "leaders"}]}]}, {"type": "partOf", "sentence": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarketsM The U.S. Insomnia Market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.", "score": 0.441394, "arguments": [{"text": "Grow", "location": [37, 41], "entities": [{"type": "Organization", "text": "Grow"}]}, {"text": "Insomnia Market Expected", "location": [9, 33], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}]}, {"type": "partOf", "sentence": "MarketsandMarketsM is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.", "score": 0.453653, "arguments": [{"text": "companies", "location": [4659, 4668], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "MarketsandMarkets\u2122", "location": [4598, 4616], "entities": [{"type": "Organization", "text": "MarketsandMarkets\u2122 The U.S. Insomnia Market"}]}]}, {"type": "locatedAt", "sentence": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarketsM The U.S. Insomnia Market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.", "score": 0.500702, "arguments": [{"text": "Grow", "location": [37, 41], "entities": [{"type": "Organization", "text": "Grow"}]}, {"text": "CAGR of", "location": [47, 54], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "hasAttribute", "sentence": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarketsM The U.S. Insomnia Market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.", "score": 0.637177, "arguments": [{"text": "MarketsandMarkets\u2122 The U.S. Insomnia Market", "location": [63, 106], "entities": [{"type": "Organization", "text": "MarketsandMarkets\u2122 The U.S. Insomnia Market"}]}, {"text": "4.24 Billion", "location": [133, 145], "entities": [{"type": "Money", "text": "4.24 Billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "RSS U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarketsM The U.S. Insomnia Market is projected to reach USD 4.24 Billion by 2021 from USD 3.38 Billion in 2016, at a CAGR of 4.6% during the forecast period.", "score": 0.46611, "arguments": [{"text": "MarketsandMarkets\u2122 The U.S. Insomnia Market", "location": [63, 106], "entities": [{"type": "Organization", "text": "MarketsandMarkets\u2122 The U.S. Insomnia Market"}]}, {"text": "3.38 Billion", "location": [163, 175], "entities": [{"type": "Money", "text": "3.38 Billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "Northbrook, IL -- ( SBWIRE ) -- 11/02/2018 -- According to a new market research report \"U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021\", published by MarketsandMarkets.", "score": 0.957497, "arguments": [{"text": "Northbrook", "location": [231, 241], "entities": [{"type": "GeopoliticalEntity", "text": "Northbrook"}]}, {"text": "IL", "location": [243, 245], "entities": [{"type": "GeopoliticalEntity", "text": "IL"}]}]}, {"type": "partOf", "sentence": "Northbrook, IL -- ( SBWIRE ) -- 11/02/2018 -- According to a new market research report \"U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021\", published by MarketsandMarkets.", "score": 0.57671, "arguments": [{"text": "Non-Pharmacological Therapy", "location": [344, 371], "entities": [{"type": "Organization", "text": "Non-Pharmacological Therapy"}]}, {"text": "Insomnia Market", "location": [325, 340], "entities": [{"type": "Organization", "text": "Insomnia Market Expected"}]}]}, {"type": "partOf", "sentence": "Northbrook, IL -- ( SBWIRE ) -- 11/02/2018 -- According to a new market research report \"U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021\", published by MarketsandMarkets.", "score": 0.403205, "arguments": [{"text": "CBTI", "location": [373, 377], "entities": [{"type": "Organization", "text": "Non-Pharmacological Therapy"}]}, {"text": "Hypnotherapy", "location": [379, 391], "entities": [{"type": "Organization", "text": "Hypnotherapy", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Speak to Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=55727597 The prescription sleep aids segment is categorized into non-benzodiazepines, benzodiazepines, orexin antagonists, melatonin receptor agonists, and other prescription sleep aids.", "score": 0.502133, "arguments": [{"text": "Analyst", "location": [1744, 1751], "entities": [{"type": "Person", "text": "Analyst"}]}, {"text": "Speak", "location": [1735, 1740], "entities": [{"type": "EventCommunication", "text": "Speak"}]}]}], "keywords": [{"text": "U.S. Insomnia Market", "sentiment": {"score": -0.409553, "label": "negative"}, "relevance": 0.989064}, {"text": "prescription sleep aids", "sentiment": {"score": -0.669636, "label": "negative"}, "relevance": 0.968601}, {"text": "sleep aids segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.721986}, {"text": "Insomnia Market Expected", "sentiment": {"score": -0.449983, "label": "negative"}, "relevance": 0.616475}, {"text": "Insomnia Market market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.596979}, {"text": "pharmacological treatment market", "sentiment": {"score": -0.574432, "label": "negative"}, "relevance": 0.587304}, {"text": "OTC sleep aids", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574105}, {"text": "antagonist sleep aids", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562999}, {"text": "over-the-counter sleep aids", "sentiment": {"score": -0.669636, "label": "negative"}, "relevance": 0.562701}, {"text": "forecast period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560452}, {"text": "OTC sleep aid", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556774}, {"text": "sleep restriction therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544952}, {"text": "non-pharmacological treatment market", "sentiment": {"score": -0.433206, "label": "negative"}, "relevance": 0.544191}, {"text": "insomnia patients", "sentiment": {"score": 0.167075, "label": "positive"}, "relevance": 0.539794}, {"text": "new market research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536864}, {"text": "insomnia cost", "sentiment": {"score": -0.477666, "label": "negative"}, "relevance": 0.531078}, {"text": "market data Tables", "sentiment": {"score": 0.228674, "label": "positive"}, "relevance": 0.529779}, {"text": "orexin antagonist", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51056}, {"text": "market research platform", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510446}, {"text": "high growth", "sentiment": {"score": 0.674082, "label": "positive"}, "relevance": 0.509775}, {"text": "melatonin receptor agonists", "sentiment": {"score": -0.241159, "label": "negative"}, "relevance": 0.507771}, {"text": "highest CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496668}, {"text": "highly recommended treatment", "sentiment": {"score": 0.497368, "label": "positive"}, "relevance": 0.495961}, {"text": "bright light therapy", "sentiment": {"score": 0.351971, "label": "positive"}, "relevance": 0.495692}, {"text": "cognitive behavioral therapy", "sentiment": {"score": -0.433206, "label": "negative"}, "relevance": 0.493998}, {"text": "sleep hygiene", "sentiment": {"score": 0.362938, "label": "positive"}, "relevance": 0.493853}, {"text": "high growth niche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.493828}, {"text": "worldwide approach MarketsandMarkets\u2122", "sentiment": {"score": -0.764143, "label": "negative"}, "relevance": 0.493678}, {"text": "high growth markets", "sentiment": {"score": 0.674082, "label": "positive"}, "relevance": 0.492718}, {"text": "quantified B2B research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48899}, {"text": "Growth Engagement Model", "sentiment": {"score": 0.739708, "label": "positive"}, "relevance": 0.488631}, {"text": "Meda Consumer Healthcare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.488488}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487437}, {"text": "MarketsandMarkets\u2122 The U.S.", "sentiment": {"score": -0.449983, "label": "negative"}, "relevance": 0.485777}, {"text": "alternative therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48453}, {"text": "Download PDF Brochure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483946}, {"text": "flagship competitive intelligence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483735}, {"text": "OTC Treatment", "sentiment": {"score": -0.201985, "label": "negative"}, "relevance": 0.482413}, {"text": "entire value chains", "sentiment": {"score": 0.574248, "label": "positive"}, "relevance": 0.479649}, {"text": "Valerian Root", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459243}, {"text": "aroma therapy", "sentiment": {"score": 0.402737, "label": "positive"}, "relevance": 0.45776}, {"text": "music therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457368}, {"text": "new drugs", "sentiment": {"score": -0.477666, "label": "negative"}, "relevance": 0.457071}, {"text": "government support", "sentiment": {"score": -0.477666, "label": "negative"}, "relevance": 0.455337}, {"text": "orexin antagonists", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454302}, {"text": "cognitive therapy", "sentiment": {"score": -0.285429, "label": "negative"}, "relevance": 0.454197}]}, "extracted_metadata": {"sha1": "27345977624ce72593483610a06d56606acb3032", "filename": "1541176665637.zip-54f49f03a8b5d65a51307c12eff7ad44.xml", "file_type": "json"}, "external_links": ["http://www.marketsandmarkets.com/Market-Reports/us-insomnia-market-55727597.html", "http://www.marketsandmarkets.com/speaktoanalyst.asp?id=55727597", "http://www.releasewire.com/rss/", "http://www.marketsandmarkets.com/pdfdownload.asp?id=55727597"], "title": "U.S. Insomnia Market Expected to Grow at a CAGR of 4.6% by MarketsandMarkets", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "dcy37qVAApDGpmTivNOJikaxumBKkDnn7oCk1HfgmVenlCTJjP9HYOVVvWk7JqY6", "result_metadata": {"score": 35.629993}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TIG Medical Equipment", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TiGenix", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "TiGenix", "dbpedia_resource": "http://dbpedia.org/resource/TiGenix"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Engineering", "relevance": 0.869974, "dbpedia_resource": "http://dbpedia.org/resource/Engineering"}], "categories": [{"score": 0.518024, "label": "/real estate/buying and selling homes"}, {"score": 0.490985, "label": "/finance/investing"}, {"score": 0.490985, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "TiGenix NV TIG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.950088}, {"text": "Alliances Profile Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.723374}, {"text": "Medical Equipment Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.684082}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25398}]}, "crawl_date": "2018-11-03T05:38:52Z", "url": "https://www.bioportfolio.com/news/article/3804147/TiGenix-NV-TIG-Medical-Equipment-Deals-and-Alliances-Profile-Report-Updated-15102018.html", "host": "bioportfolio.com", "text": "TiGenix NV TIG Medical Equipment Deals and Alliances Profile [Report Updated: 15102018] Prices from USD $250 01:19 EDT 3 Nov 2018 | BioPortfolio Reports Summary TiGenix NV TiGenix, a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-03T05:19:00Z", "enriched_text": {"entities": [{"count": 31, "sentiment": {"score": 0.112399, "label": "positive"}, "text": "target Company", "relevance": 0.872451, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.519876, "label": "positive"}, "text": "TiGenix NV TiGenix", "relevance": 0.308784, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.483359, "label": "positive"}, "text": "TiGenix", "relevance": 0.21253, "type": "Company", "disambiguation": {"subtype": [], "name": "TiGenix", "dbpedia_resource": "http://dbpedia.org/resource/TiGenix"}}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.203571, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.483359, "label": "positive"}, "text": "Alliances Profile", "relevance": 0.188743, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.483359, "label": "positive"}, "text": "TIG Medical Equipment", "relevance": 0.172969, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.167143, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceutical and Healthcare News", "relevance": 0.158681, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical eTrack", "relevance": 0.157013, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Leuven", "relevance": 0.156494, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Leuven", "dbpedia_resource": "http://dbpedia.org/resource/Leuven"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.15344, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Belgium", "relevance": 0.146275, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Belgium", "dbpedia_resource": "http://dbpedia.org/resource/Belgium"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.138687, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.137622, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.136436, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.135066, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.131851, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.125404, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.123479, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.122336, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Netherlands", "relevance": 0.110715, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.110715, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 01", "relevance": 0.110715, "type": "Quantity"}], "sentiment": {"document": {"score": 0.419967, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "TiGenix NV TiGenix, a subsidiary of Takeda Pharmaceutical Co Ltd,", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "TiGenix NV TiGenix"}, {"text": "subsidiary"}], "entities": [{"type": "Company", "text": "TiGenix NV TiGenix"}, {"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "sentence": " TiGenix NV TiGenix, a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products.", "object": {"text": "a biopharmaceutical company that develops and commercializes novel therapeutic products", "keywords": [{"text": "novel therapeutic products"}, {"text": "biopharmaceutical company"}], "entities": [{"type": "Company", "text": "TiGenix NV TiGenix"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a biopharmaceutical company", "keywords": [{"text": "biopharmaceutical company"}], "entities": [{"type": "Company", "text": "TiGenix NV TiGenix"}]}, "sentence": " TiGenix NV TiGenix, a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products.", "object": {"text": "novel therapeutic products", "keywords": [{"text": "novel therapeutic products"}]}, "action": {"verb": {"text": "commercialize", "tense": "present"}, "text": "develops and commercializes", "normalized": "develop and commercialize"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company exploits the antiinflammatory properties of stem cells to develop novel therapies.", "object": {"text": "the antiinflammatory properties of stem cells", "keywords": [{"text": "stem cells"}, {"text": "antiinflammatory properties"}], "entities": []}, "action": {"verb": {"text": "exploit", "tense": "present"}, "text": "exploits", "normalized": "exploit"}}, {"subject": {"text": "the antiinflammatory properties of stem cells", "keywords": [{"text": "stem cells"}, {"text": "antiinflammatory properties"}], "entities": []}, "sentence": " The company exploits the antiinflammatory properties of stem cells to develop novel therapies.", "object": {"text": "novel therapies", "keywords": [{"text": "novel therapies"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "It"}, "sentence": " It offers products such as AlloCSC01, AlloCSC02, Cx611 and Cx601.", "object": {"text": "products such as AlloCSC01, AlloCSC02, Cx611 and Cx601", "keywords": [{"text": "products"}, {"text": "AlloCSC01"}, {"text": "AlloCSC02"}, {"text": "Cx611"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "TiGenix", "keywords": [{"text": "TiGenix"}], "entities": [{"type": "Company", "text": "TiGenix NV TiGenix", "disambiguation": {"subtype": [], "name": "TiGenix", "dbpedia_resource": "http://dbpedia.org/resource/TiGenix"}}]}, "sentence": " TiGenix develops its products using expanded stem cells extracted from adipose tissue platform.", "object": {"text": "its products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "cells", "keywords": [{"text": "cells"}]}, "sentence": " TiGenix develops its products using expanded stem cells extracted from adipose tissue platform.", "object": {"text": "from adipose tissue platform", "keywords": [{"text": "tissue platform"}]}, "action": {"verb": {"text": "extract", "tense": "past"}, "text": "extracted", "normalized": "extract"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company has operations in Spain, the US, the Netherlands and Belgium.", "object": {"text": "operations in Spain, the US, the Netherlands and Belgium", "keywords": [{"text": "operations"}, {"text": "Spain"}, {"text": "Netherlands"}, {"text": "Belgium"}], "entities": [{"type": "Location", "text": "Spain", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Netherlands", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Belgium", "disambiguation": {"subtype": ["HumanLanguage", "Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Belgium", "dbpedia_resource": "http://dbpedia.org/resource/Belgium"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "TiGenix", "keywords": [{"text": "TiGenix"}], "entities": [{"type": "Company", "text": "TiGenix NV TiGenix", "disambiguation": {"subtype": [], "name": "TiGenix", "dbpedia_resource": "http://dbpedia.org/resource/TiGenix"}}]}, "sentence": " TiGenix is headquartered in Leuven, Belgium.", "object": {"text": "headquartered in Leuven", "keywords": [{"text": "Leuven"}], "entities": [{"type": "Location", "text": "Leuven", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Leuven", "dbpedia_resource": "http://dbpedia.org/resource/Leuven"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "TiGenix", "keywords": [{"text": "TiGenix"}], "entities": [{"type": "Company", "text": "TiGenix NV TiGenix", "disambiguation": {"subtype": [], "name": "TiGenix", "dbpedia_resource": "http://dbpedia.org/resource/TiGenix"}}]}, "sentence": " TiGenix is headquartered in Leuven, Belgium.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "TiGenix NV TIG Medical Equipment Deals and Alliances Profile", "keywords": [{"text": "TiGenix NV TIG"}, {"text": "Medical Equipment Deals"}, {"text": "Alliances Profile"}], "entities": [{"type": "Company", "text": "TiGenix", "disambiguation": {"subtype": [], "name": "TiGenix", "dbpedia_resource": "http://dbpedia.org/resource/TiGenix"}}, {"type": "Company", "text": "TIG Medical Equipment"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " TiGenix NV TIG Medical Equipment Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Company", "text": "target Company"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Finance", "relevance": 0.940847, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Venture capital", "relevance": 0.929874, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Mergers and acquisitions", "relevance": 0.870106, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Corporate finance", "relevance": 0.775803, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Investment", "relevance": 0.715483, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Corporation", "relevance": 0.679386, "dbpedia_resource": "http://dbpedia.org/resource/Corporation"}], "categories": [{"score": 0.642399, "label": "/finance/financial news"}, {"score": 0.433627, "label": "/business and industrial"}, {"score": 0.420987, "label": "/business and industrial/business operations"}], "relations": [{"type": "timeOf", "sentence": "TiGenix NV TIG Medical Equipment Deals and Alliances Profile [Report Updated: 15102018] Prices from USD $250 01:19 EDT 3 Nov 2018 | BioPortfolio Reports Summary TiGenix NV TiGenix, a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products.", "score": 0.37387, "arguments": [{"text": "01:19", "location": [109, 114], "entities": [{"type": "Time", "text": "01:19"}]}, {"text": "Report", "location": [62, 68], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.689884, "arguments": [{"text": "competitors", "location": [2947, 2958], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [2966, 2973], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.374818, "arguments": [{"text": "you", "location": [3126, 3129], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3148, 3155], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3222, 3225], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3229, 3236], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "employedBy", "sentence": "Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "score": 0.284605, "arguments": [{"text": "customers", "location": [3962, 3971], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "company", "location": [3919, 3926], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}, {"type": "locatedAt", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.337955, "arguments": [{"text": "company", "location": [4012, 4019], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}, {"text": "locations", "location": [4042, 4051], "entities": [{"type": "Location", "text": "locations"}]}]}, {"type": "partOf", "sentence": "TiGenix NV TIG Medical Equipment Deals and Alliances Profile [Report Updated: 15102018] Prices from USD $250 01:19 EDT 3 Nov 2018 | BioPortfolio Reports Summary TiGenix NV TiGenix, a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products.", "score": 0.402941, "arguments": [{"text": "subsidiary", "location": [183, 193], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}, {"text": "Takeda Pharmaceutical Co Ltd", "location": [197, 225], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "TiGenix is headquartered in Leuven, Belgium.", "score": 0.322771, "arguments": [{"text": "TiGenix", "location": [844, 851], "entities": [{"type": "Person", "text": "Summary\nTiGenix NV TiGenix"}]}, {"text": "Leuven", "location": [872, 878], "entities": [{"type": "GeopoliticalEntity", "text": "Leuven"}]}]}, {"type": "locatedAt", "sentence": "TiGenix is headquartered in Leuven, Belgium.", "score": 0.984789, "arguments": [{"text": "Leuven", "location": [872, 878], "entities": [{"type": "GeopoliticalEntity", "text": "Leuven"}]}, {"text": "Belgium", "location": [880, 887], "entities": [{"type": "GeopoliticalEntity", "text": "Belgium", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "productOf", "sentence": "TiGenix NV TIG Medical Equipment Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.879634, "arguments": [{"text": "Mergers", "location": [1018, 1025], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1008, 1015], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}, {"type": "productOf", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.535319, "arguments": [{"text": "Mergers", "location": [1636, 1643], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1600, 1607], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.699349, "arguments": [{"text": "Asia", "location": [2235, 2239], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2240, 2247], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [2615, 2624], "entities": [{"type": "Organization", "text": "biotechnology companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2592, 2599], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.438716, "arguments": [{"text": "executives", "location": [2761, 2771], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [2779, 2786], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.713979, "arguments": [{"text": "subsidiaries", "location": [2884, 2896], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "company", "location": [2904, 2911], "entities": [{"type": "Organization", "text": "AlloCSC01"}]}]}], "keywords": [{"text": "deals", "sentiment": {"score": 0.458249, "label": "positive"}, "relevance": 0.976179}, {"text": "financial deals", "sentiment": {"score": 0.572001, "label": "positive"}, "relevance": 0.957398}, {"text": "company", "sentiment": {"score": -0.0236335, "label": "negative"}, "relevance": 0.940153}, {"text": "Medical Equipment Deals", "sentiment": {"score": 0.483359, "label": "positive"}, "relevance": 0.859641}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612821}, {"text": "Financial Deals Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609101}, {"text": "eTrack deals database", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605651}, {"text": "major financial deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602352}, {"text": "TIG Medical Equipment", "sentiment": {"score": 0.483359, "label": "positive"}, "relevance": 0.597956}, {"text": "NV TIG Medical", "sentiment": {"score": 0.483359, "label": "positive"}, "relevance": 0.594358}, {"text": "TiGenix NV TIG", "sentiment": {"score": 0.483359, "label": "positive"}, "relevance": 0.592898}, {"text": "detailed major deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573511}, {"text": "recent financial deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.570481}, {"text": "major recent deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561594}, {"text": "key deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.483683}, {"text": "detailed information", "sentiment": {"score": 0.677039, "label": "positive"}, "relevance": 0.436817}, {"text": "key competitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413047}, {"text": "TiGenix NV TiGenix", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383317}, {"text": "business segments", "sentiment": {"score": -0.352689, "label": "negative"}, "relevance": 0.382856}, {"text": "target company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371408}, {"text": "key financial metrics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370627}, {"text": "Alliances Profile", "sentiment": {"score": 0.483359, "label": "positive"}, "relevance": 0.368492}, {"text": "stem cells", "sentiment": {"score": -0.315557, "label": "negative"}, "relevance": 0.36107}, {"text": "novel therapeutic products", "sentiment": {"score": 0.519876, "label": "positive"}, "relevance": 0.353776}, {"text": "Private Equity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346777}, {"text": "Venture Financing", "sentiment": {"score": 0.489186, "label": "positive"}, "relevance": 0.346154}, {"text": "adipose tissue platform", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344139}, {"text": "detailed comparative data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342843}, {"text": "Equity/Debt Offerings", "sentiment": {"score": 0.343645, "label": "positive"}, "relevance": 0.342651}, {"text": "Gain key insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338072}, {"text": "Access elaborate information", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.336222}, {"text": "biopharmaceutical company", "sentiment": {"score": 0.519876, "label": "positive"}, "relevance": 0.333797}, {"text": "key executives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333277}, {"text": "major public companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330472}, {"text": "core business segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329577}, {"text": "expanded stem cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.327573}, {"text": "business research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.300355}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.283303}, {"text": "Subsector Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263242}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252382}, {"text": "BioPortfolio Reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25189}, {"text": "key centers", "sentiment": {"score": 0.539694, "label": "positive"}, "relevance": 0.251511}, {"text": "Key elements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247948}, {"text": "Report Updated", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246284}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245745}, {"text": "antiinflammatory properties", "sentiment": {"score": -0.315557, "label": "negative"}, "relevance": 0.241141}, {"text": "Acquisitions MAs", "sentiment": {"score": 0.570534, "label": "positive"}, "relevance": 0.238329}, {"text": "offers products", "sentiment": {"score": -0.829635, "label": "negative"}, "relevance": 0.235356}, {"text": "Type Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233823}, {"text": "novel therapies", "sentiment": {"score": -0.315557, "label": "negative"}, "relevance": 0.23315}]}, "extracted_metadata": {"sha1": "772caeb6742d451542ae4e55669346d452732a96", "filename": "1541223532909.zip-4da8bc7545c71016248bd9c2fc1e66c3.xml", "file_type": "json"}, "title": "TiGenix NV TIG Medical Equipment Deals and Alliances Profile Report Updated 15102018 Prices from USD $250", "forum_title": "BioPortfolio Latest News"}, {"id": "5AThx90aAfw7GIROh1JpOQ4tX0ryq39sxVbA71F6sOZkhegRyDHHfKQYto8PeHBh", "result_metadata": {"score": 34.903023}, "author": "sproutnews", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Integrin alpha M", "relevance": 0.845794, "dbpedia_resource": "http://dbpedia.org/resource/Integrin_alpha_M"}, {"text": "Trade", "relevance": 0.718901, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}], "categories": [{"score": 0.518959, "label": "/finance/financial news"}, {"score": 0.504036, "label": "/real estate/buying and selling homes"}, {"score": 0.477012, "label": "/finance/investing"}], "relations": [], "keywords": [{"text": "Global Integrin Alpha", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975159}, {"text": "Market Revenue Status", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.787445}, {"text": "Outlook", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351017}]}, "crawl_date": "2018-11-02T19:06:27Z", "url": "http://sproutnews.com/global-integrin-alpha-4-market-revenue-status-and-outlook-2013-2025/", "host": "sproutnews.com", "text": "Key companies profiled in this report are Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, Biomas Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Immunwork Inc, Morphic Therapeutic Inc, Protagonist Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Viriom Inc and others.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T13:25:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Integrin Alpha", "relevance": 0.942538, "type": "GeographicFeature"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amgen Inc", "relevance": 0.308832, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pune", "relevance": 0.249071, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Pune", "dbpedia_resource": "http://dbpedia.org/resource/Pune"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Co Ltd", "relevance": 0.239516, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Antisense Therapeutics Ltd", "relevance": 0.227388, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EA Pharma Co Ltd", "relevance": 0.226756, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.224423, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Protagonist Therapeutics Inc", "relevance": 0.219666, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.21551, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Morphic Therapeutic Inc", "relevance": 0.204117, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen Inc", "relevance": 0.201972, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Viriom Inc", "relevance": 0.200589, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biomas Ltd", "relevance": 0.199485, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Immunwork Inc", "relevance": 0.192568, "type": "Company"}], "sentiment": {"document": {"score": 0.534541, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "That"}, "sentence": " That makes this report so invaluable, resources, for the leaders as well as the new entrants in the Industry", "object": {"text": "this report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "All these"}, "sentence": " All these are offshoots of understanding the current situation that the industry is in, especially in 2018.", "object": {"text": "offshoots of understanding the current situation", "keywords": [{"text": "current situation"}, {"text": "offshoots"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The"}, "sentence": " The will chart the course for a more comprehensive organization and discernment of the competition situation in the Integrin Alpha 4 market.", "object": {"text": "the course for a more comprehensive organization and discernment of the competition situation in the Integrin Alpha 4 market", "keywords": [{"text": "Integrin Alpha"}, {"text": "competition situation"}, {"text": "comprehensive organization"}, {"text": "discernment"}], "entities": [{"type": "GeographicFeature", "text": "Integrin Alpha"}]}, "action": {"verb": {"text": "chart", "tense": "future"}, "text": "will chart", "normalized": "will chart"}}, {"subject": {"text": "this"}, "sentence": " As this will help manufacturers and investors alike, to have a better understanding of the direction in which the Integrin Alpha 4 Market is headed.", "object": {"text": "manufacturers and investors alike", "keywords": [{"text": "investors"}, {"text": "manufacturers"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "will help", "normalized": "will help"}}, {"subject": {"text": "one"}, "sentence": " With this Integrin Alpha 4 Market report, one is sure to keep up with information on the dogged competition for market share and control, between elite manufacturers.", "object": {"text": "with information on the dogged competition for market share and control", "keywords": [{"text": "dogged competition"}, {"text": "market share"}, {"text": "information"}, {"text": "control"}]}, "action": {"verb": {"text": "keep", "tense": "future"}, "text": "to keep", "normalized": "to keep"}}, {"subject": {"text": "It"}, "sentence": " It also features, price, production, and revenue.", "object": {"text": "production, and revenue", "keywords": [{"text": "revenue"}, {"text": "production"}]}, "action": {"verb": {"text": "feature", "tense": "present"}, "text": "features", "normalized": "feature"}}, {"subject": {"text": "you"}, "sentence": " It is where you will understand the politics and tussle of gaining control of a huge chunk of the market share.", "object": {"text": "the politics and tussle of gaining control of a huge chunk of the market share", "keywords": [{"text": "huge chunk"}, {"text": "tussle"}, {"text": "market share"}, {"text": "politics"}]}, "action": {"verb": {"text": "understand", "tense": "future"}, "text": "will understand", "normalized": "will understand"}}, {"subject": {"text": "you"}, "sentence": " It is where you will understand the politics and tussle of gaining control of a huge chunk of the market share.", "object": {"text": "control", "keywords": [{"text": "control"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "gaining", "normalized": "gain"}}, {"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " As long as you are in search of key Industry data and information that can readily be accessed, you can rest assured that this report got them covered.", "object": {"text": "them covered"}, "action": {"verb": {"text": "get", "tense": "past"}, "text": "got", "normalized": "get"}}, {"subject": {"text": "Key companies", "keywords": [{"text": "Key companies"}], "entities": [{"type": "Company", "text": "Amgen Inc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}]}, "sentence": " Key companies profiled in this report are Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, Biomas Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Immunwork Inc, Morphic Therapeutic Inc, Protagonist Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Viriom Inc and others.", "action": {"verb": {"text": "profile", "tense": "past"}, "text": "profiled", "normalized": "profile"}}, {"subject": {"text": "it"}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "a good look at this report", "keywords": [{"text": "good look"}, {"text": "report"}]}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "taking", "normalized": "take"}}, {"subject": {"text": "this report", "keywords": [{"text": "report"}]}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "on the product", "keywords": [{"text": "product"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "the rate of production, price, revenue, and market share as well as of the growth of each product type", "keywords": [{"text": "market share"}, {"text": "product type"}, {"text": "revenue"}, {"text": "rate"}]}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "evident that the report shows", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " When taking a good look at this report, based on the product, it is evident that the report shows the rate of production, price, revenue, and market share as well as of the growth of each product type.", "object": {"text": "the rate of production, price, revenue, and market share as well as of the growth of each product type", "keywords": [{"text": "market share"}, {"text": "product type"}, {"text": "revenue"}, {"text": "rate"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "shows", "normalized": "show"}}, {"subject": {"text": "emphasis", "keywords": [{"text": "emphasis"}]}, "sentence": " And emphasis is laid on the end users, as well as on the applications of the product.", "object": {"text": "laid on the end users", "keywords": [{"text": "end users"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "emphasis", "keywords": [{"text": "emphasis"}]}, "sentence": " And emphasis is laid on the end users, as well as on the applications of the product.", "object": {"text": "on the end users", "keywords": [{"text": "end users"}]}, "action": {"verb": {"text": "lay", "tense": "past"}, "text": "is laid", "normalized": "be lay"}}, {"subject": {"text": "one report", "keywords": [{"text": "report"}]}, "sentence": " It is one report that hasn\u2019t shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications.", "object": {"text": "n\u2019t shied"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}], "concepts": [{"text": "Marketing", "relevance": 0.950023, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Manufacturing", "relevance": 0.457769, "dbpedia_resource": "http://dbpedia.org/resource/Manufacturing"}, {"text": "Daiichi Sankyo", "relevance": 0.438393, "dbpedia_resource": "http://dbpedia.org/resource/Daiichi_Sankyo"}, {"text": "Future", "relevance": 0.437502, "dbpedia_resource": "http://dbpedia.org/resource/Future"}, {"text": "Biogen Idec", "relevance": 0.435653, "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}, {"text": "Amgen", "relevance": 0.418236, "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}, {"text": "Marketing research", "relevance": 0.410063, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_research"}, {"text": "Abbas Kiarostami", "relevance": 0.40986, "dbpedia_resource": "http://dbpedia.org/resource/Abbas_Kiarostami"}], "categories": [{"score": 0.51913, "label": "/finance/financial news"}, {"score": 0.491232, "label": "/business and industrial/manufacturing"}, {"score": 0.48963, "label": "/business and industrial/business operations/management/business process"}], "relations": [{"type": "partOf", "sentence": "Content Marketing & Distribution News Release Broadcast What We Do Newsroom Contact Us Global Integrin Alpha 4 Market Revenue Status and Outlook (2013-2025) Global Integrin Alpha 4 Market Research Report 2018 contains historic data that spans 2013 to 2017, and then continues to forecast to 2025.", "score": 0.57877, "arguments": [{"text": "Global Integrin Alpha 4 Market Research Report", "location": [157, 203], "entities": [{"type": "Organization", "text": "Global Integrin Alpha 4 Market Research Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Content Marketing & Distribution News Release Broadcast What We Do Newsroom Contact Us Global Integrin Alpha 4 Market Revenue Status and Outlook", "location": [0, 144], "entities": [{"type": "Organization", "text": "Content Marketing & Distribution News Release Broadcast What We Do Newsroom Contact Us Global Integrin Alpha 4 Market Revenue Status and Outlook"}]}]}, {"type": "employedBy", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1168595 List of Chapters: 1 Integrin Alpha 4 Market Overview 2 Global Integrin Alpha 4 Market Competitions by Manufacturers 3 Global Integrin Alpha 4 Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Integrin Alpha 4 Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Integrin Alpha 4 Production, Revenue (Value), Price Trend by Type 6 Global Integrin Alpha 4 Market Analysis by Application 7 Global Integrin Alpha 4 Manufacturers Profiles/Analysis 8 Integrin Alpha 4 Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Integrin Alpha 4 Market Forecast (2018-2025)", "score": 0.646757, "arguments": [{"text": "Price Trend", "location": [3123, 3134], "entities": [{"type": "Person", "text": "Price Trend"}]}, {"text": "Type 6 Global Integrin Alpha 4 Market Analysis", "location": [3138, 3184], "entities": [{"type": "Organization", "text": "Type 6 Global Integrin Alpha 4 Market Analysis"}]}]}, {"type": "locatedAt", "sentence": "That makes this report so invaluable, resources, for the leaders as well as the new entrants in the Industry Pune, India - November 2, 2018 /MarketersMedia/ \u2014 Global Integrin Alpha 4 Market report is replete with detailed analysis from a thorough research, especially on questions that border on market size, development environment, futuristic developments, operation situation, pathways and trend of Integrin Alpha 4.", "score": 0.97087, "arguments": [{"text": "Industry\nPune", "location": [397, 410], "entities": [{"type": "GeopoliticalEntity", "text": "Industry\nPune"}]}, {"text": "India", "location": [412, 417], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "As long as you are in search of key Industry data and information that can readily be accessed, you can rest assured that this report got them covered.", "score": 0.769801, "arguments": [{"text": "you", "location": [1659, 1662], "entities": [{"type": "Person", "text": "you"}]}, {"text": "assured", "location": [1672, 1679], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Key companies profiled in this report are Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, Biomas Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Immunwork Inc, Morphic Therapeutic Inc, Protagonist Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Viriom Inc and others.", "score": 0.40399, "arguments": [{"text": "Amgen Inc", "location": [1757, 1766], "entities": [{"type": "Organization", "text": "Amgen Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1719, 1728], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Key companies profiled in this report are Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, Biomas Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Immunwork Inc, Morphic Therapeutic Inc, Protagonist Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Viriom Inc and others.", "score": 0.750517, "arguments": [{"text": "Antisense Therapeutics Ltd", "location": [1768, 1794], "entities": [{"type": "Organization", "text": "Antisense Therapeutics Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1719, 1728], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1168595 List of Chapters: 1 Integrin Alpha 4 Market Overview 2 Global Integrin Alpha 4 Market Competitions by Manufacturers 3 Global Integrin Alpha 4 Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Integrin Alpha 4 Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Integrin Alpha 4 Production, Revenue (Value), Price Trend by Type 6 Global Integrin Alpha 4 Market Analysis by Application 7 Global Integrin Alpha 4 Manufacturers Profiles/Analysis 8 Integrin Alpha 4 Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Integrin Alpha 4 Market Forecast (2018-2025)", "score": 0.667816, "arguments": [{"text": "Manufacturers 3 Global Integrin Alpha 4 Capacity", "location": [2871, 2919], "entities": [{"type": "Organization", "text": "Manufacturers 3 Global Integrin Alpha 4 Capacity"}]}, {"text": "Integrin Alpha 4 Market Overview 2 Global Integrin Alpha 4 Market Competitions", "location": [2789, 2867], "entities": [{"type": "Organization", "text": "Integrin Alpha 4 Market Overview 2 Global Integrin Alpha 4 Market Competitions"}]}]}, {"type": "locatedAt", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1168595 List of Chapters: 1 Integrin Alpha 4 Market Overview 2 Global Integrin Alpha 4 Market Competitions by Manufacturers 3 Global Integrin Alpha 4 Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Integrin Alpha 4 Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Integrin Alpha 4 Production, Revenue (Value), Price Trend by Type 6 Global Integrin Alpha 4 Market Analysis by Application 7 Global Integrin Alpha 4 Manufacturers Profiles/Analysis 8 Integrin Alpha 4 Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Integrin Alpha 4 Market Forecast (2018-2025)", "score": 0.924432, "arguments": [{"text": "Consumption", "location": [3018, 3029], "entities": [{"type": "GeopoliticalEntity", "text": "Consumption"}]}, {"text": "Export", "location": [3031, 3037], "entities": [{"type": "GeopoliticalEntity", "text": "Export"}]}]}, {"type": "locatedAt", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1168595 List of Chapters: 1 Integrin Alpha 4 Market Overview 2 Global Integrin Alpha 4 Market Competitions by Manufacturers 3 Global Integrin Alpha 4 Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Integrin Alpha 4 Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Integrin Alpha 4 Production, Revenue (Value), Price Trend by Type 6 Global Integrin Alpha 4 Market Analysis by Application 7 Global Integrin Alpha 4 Manufacturers Profiles/Analysis 8 Integrin Alpha 4 Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Integrin Alpha 4 Market Forecast (2018-2025)", "score": 0.581223, "arguments": [{"text": "Export", "location": [3031, 3037], "entities": [{"type": "GeopoliticalEntity", "text": "Export"}]}, {"text": "Import", "location": [3039, 3045], "entities": [{"type": "GeopoliticalEntity", "text": "Import"}]}]}, {"type": "locatedAt", "sentence": "All the queries about this report can be asked at: https://www.themarketreports.com/report/ask-your-query/1168595 List of Chapters: 1 Integrin Alpha 4 Market Overview 2 Global Integrin Alpha 4 Market Competitions by Manufacturers 3 Global Integrin Alpha 4 Capacity, Production, Revenue (Value) by Region (2013-2018) 4 Global Integrin Alpha 4 Supply (Production), Consumption, Export, Import by Region (2013-2018) 5 Global Integrin Alpha 4 Production, Revenue (Value), Price Trend by Type 6 Global Integrin Alpha 4 Market Analysis by Application 7 Global Integrin Alpha 4 Manufacturers Profiles/Analysis 8 Integrin Alpha 4 Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Integrin Alpha 4 Market Forecast (2018-2025)", "score": 0.493297, "arguments": [{"text": "Import", "location": [3039, 3045], "entities": [{"type": "GeopoliticalEntity", "text": "Import"}]}, {"text": "Region", "location": [3049, 3055], "entities": [{"type": "GeopoliticalEntity", "text": "Region"}]}]}], "keywords": [{"text": "Integrin Alpha", "sentiment": {"score": 0.592105, "label": "positive"}, "relevance": 0.961147}, {"text": "Global Integrin Alpha", "sentiment": {"score": 0.566084, "label": "positive"}, "relevance": 0.901348}, {"text": "market share", "sentiment": {"score": -0.0991887, "label": "negative"}, "relevance": 0.384383}, {"text": "Market Revenue Status", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338896}, {"text": "Market Research Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33766}, {"text": "Market report", "sentiment": {"score": 0.566084, "label": "positive"}, "relevance": 0.30738}, {"text": "Access complete report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306232}, {"text": "market share control", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306174}, {"text": "Distribution News Release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.304951}, {"text": "contains historic data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303287}, {"text": "Market Effect Factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.29667}, {"text": "key Industry data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.289849}, {"text": "Manufacturing Cost Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.287717}, {"text": "Marketing Strategy Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.286516}, {"text": "end users", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281706}, {"text": "market size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270217}, {"text": "Contact Us Global", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26829}, {"text": "Market Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265042}, {"text": "Market Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263312}, {"text": "Market Competitions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263224}, {"text": "Market Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262226}, {"text": "new entrants", "sentiment": {"score": 0.5792, "label": "positive"}, "relevance": 0.257751}, {"text": "Content Marketing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256619}, {"text": "operation situation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256551}, {"text": "Daiichi Sankyo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256153}, {"text": "current situation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256143}, {"text": "detailed analysis", "sentiment": {"score": 0.566084, "label": "positive"}, "relevance": 0.255398}, {"text": "competition situation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.255006}, {"text": "dogged competition", "sentiment": {"score": 0.45741, "label": "positive"}, "relevance": 0.253291}, {"text": "development environment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252293}, {"text": "futuristic developments", "sentiment": {"score": 0.529962, "label": "positive"}, "relevance": 0.252213}, {"text": "Antisense Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252174}, {"text": "Protagonist Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251727}, {"text": "thorough research", "sentiment": {"score": 0.566084, "label": "positive"}, "relevance": 0.251665}, {"text": "comprehensive organization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251362}, {"text": "better understanding", "sentiment": {"score": 0.618125, "label": "positive"}, "relevance": 0.250319}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250134}, {"text": "huge chunk", "sentiment": {"score": -0.580499, "label": "negative"}, "relevance": 0.249623}, {"text": "elite manufacturers", "sentiment": {"score": 0.56671, "label": "positive"}, "relevance": 0.249443}, {"text": "EA Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248787}, {"text": "Morphic Therapeutic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247864}, {"text": "Manufacturers Profiles/Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247786}, {"text": "Key companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247784}, {"text": "Price Trend", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247121}, {"text": "good look", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246726}, {"text": "product type", "sentiment": {"score": 0.505211, "label": "positive"}, "relevance": 0.246626}, {"text": "Industrial Chain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246338}, {"text": "critical look", "sentiment": {"score": -0.553296, "label": "negative"}, "relevance": 0.245598}, {"text": "Downstream Buyers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245415}]}, "extracted_metadata": {"sha1": "d0782f2f9dcbaedb42c6195d1467c6e3b8c605dc", "filename": "1541185587005.zip-9fc3fb68c50a40c3e335c185f7fa9eb9.xml", "file_type": "json"}, "external_links": ["https://www.themarketreports.com/report/ask-your-query/1168595", "https://www.themarketreports.com/report/buy-now/1168595", "https://www.themarketreports.com/report/global-integrin-alpha-4-market-research-report-2018"], "title": "Global Integrin Alpha 4 Market Revenue Status and Outlook (2013-2025)", "forum_title": "SproutNews"}, {"id": "35Fk2BdcqtQP6DILpyqxZzpck3aoz4GbPl_IOJVBLkjKjTNtWxDHSdc7kKV31Z9P", "result_metadata": {"score": 32.87108}, "author": "Ankush Nikam", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.605324, "label": "/health and fitness/disease/cancer"}, {"score": 0.469763, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [], "keywords": [{"text": "Kinase Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.923114}, {"text": "Cancer Treatment Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.723658}, {"text": "Detailed Analytical Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.71178}]}, "crawl_date": "2018-11-02T15:15:20Z", "url": "https://www.findmarketresearch.org/2018/09/kinase-inhibitors-for-cancer-treatment-market-detailed-analytical-overview-by-2026/", "host": "findmarketresearch.org", "text": "Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-09-20T10:16:00+05:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": -0.640706, "label": "negative"}, "text": "cancer", "relevance": 0.878481, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 3, "sentiment": {"score": -0.216194, "label": "negative"}, "text": "North America", "relevance": 0.686702, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 3, "sentiment": {"score": 0.265379, "label": "positive"}, "text": "Western Europe", "relevance": 0.662185, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.620534, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.536756, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.521781, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.239557, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.462678, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.459121, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": -0.361238, "label": "negative"}, "text": "Pfizer Inc.", "relevance": 0.441014, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.426305, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.418355, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Incyte Corporation", "relevance": 0.417942, "type": "Company", "disambiguation": {"subtype": [], "name": "Incyte", "dbpedia_resource": "http://dbpedia.org/resource/Incyte"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MedImmune", "relevance": 0.411278, "type": "Company", "disambiguation": {"subtype": [], "name": "MedImmune", "dbpedia_resource": "http://dbpedia.org/resource/MedImmune"}}, {"count": 1, "sentiment": {"score": -0.216194, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.395021, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.394256, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.382843, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.362799, "type": "Company"}], "sentiment": {"document": {"score": -0.634913, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Kinase Inhibitors", "keywords": [{"text": "Kinase Inhibitors"}]}, "sentence": "Kinase Inhibitors are specific enzymes which oppose the process of cell division and growth in cancerous cells.", "object": {"text": "specific enzymes which oppose the process of cell division", "keywords": [{"text": "specific enzymes"}, {"text": "cell division"}, {"text": "process"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "specific enzymes", "keywords": [{"text": "specific enzymes"}]}, "sentence": "Kinase Inhibitors are specific enzymes which oppose the process of cell division and growth in cancerous cells.", "object": {"text": "the process of cell division and growth in cancerous cells", "keywords": [{"text": "cell division"}, {"text": "process"}, {"text": "growth"}], "entities": []}, "action": {"verb": {"text": "oppose", "tense": "present"}, "text": "oppose", "normalized": "oppose"}}, {"subject": {"text": "the signals", "keywords": [{"text": "signals"}]}, "sentence": " It comes handy in treatment of cancer by blocking the signals that notify a cell to divide and grow.", "object": {"text": "a cell", "keywords": [{"text": "cell"}]}, "action": {"verb": {"text": "notify", "tense": "present"}, "text": "notify", "normalized": "notify"}}, {"subject": {"text": "there"}, "sentence": " In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy.", "object": {"text": "been significant progress made in the development of cancer treatment such as chemotherapy", "keywords": [{"text": "cancer treatment"}, {"text": "chemotherapy"}, {"text": "development"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "significant progress made in the development of cancer treatment such as chemotherapy", "keywords": [{"text": "significant progress"}, {"text": "chemotherapy"}, {"text": "cancer treatment"}, {"text": "development"}]}, "sentence": " In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "significant progress", "keywords": [{"text": "significant progress"}]}, "sentence": " In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy.", "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "these drugs used cancer treatment", "keywords": [{"text": "drugs"}, {"text": "cancer treatment"}]}, "sentence": " However, these drugs used cancer treatment have a restricted therapeutic index, also the result are only unpredictable, partial, brief, palliative as well as uncertain.", "object": {"text": "a restricted therapeutic index", "keywords": [{"text": "therapeutic index"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "kinase inhibitor therapy", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "kinase inhibitor therapy", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "object": {"text": "introduced"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "kinase inhibitor therapy", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "action": {"verb": {"text": "introduce", "tense": "past"}, "text": "introduced", "normalized": "introduce"}}, {"subject": {"text": "kinase inhibitor therapy which has recently been introduced", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "object": {"text": "specifically targeted towards cancer molecules", "keywords": [{"text": "cancer molecules"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Such targets", "keywords": [{"text": "targets"}]}, "sentence": " Such targets are normally found in tumor cells, resulting wider therapeutic index and minimum adverse effect.", "object": {"text": "normally found in tumor cells", "keywords": [{"text": "tumor cells"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Such targets", "keywords": [{"text": "targets"}]}, "sentence": " Such targets are normally found in tumor cells, resulting wider therapeutic index and minimum adverse effect.", "action": {"verb": {"text": "find", "tense": "past"}, "text": "are normally found", "normalized": "be normally find"}}, {"subject": {"text": "Significant changes", "keywords": [{"text": "Significant changes"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "object": {"text": "made in cancer treatment", "keywords": [{"text": "cancer treatment"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Significant changes", "keywords": [{"text": "Significant changes"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "action": {"verb": {"text": "make", "tense": "past"}, "text": "have been made", "normalized": "have be make"}}, {"subject": {"text": "to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth", "keywords": [{"text": "particular molecular target"}, {"text": "tumor development"}, {"text": "important role"}, {"text": "protein"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "object": {"text": "anticancer treatment", "keywords": [{"text": "anticancer treatment"}]}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "intended", "normalized": "intend"}}, {"subject": {"text": "a latest generation of anticancer treatment", "keywords": [{"text": "anticancer treatment"}, {"text": "latest generation"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "object": {"text": "with a particular molecular target, normally a protein with an important role in tumor development or growth", "keywords": [{"text": "particular molecular target"}, {"text": "tumor development"}, {"text": "important role"}, {"text": "protein"}]}, "action": {"verb": {"text": "interfere", "tense": "future"}, "text": "are intended to interfere", "normalized": "be intend to interfere"}}, {"subject": {"text": "the more observed approach", "keywords": [{"text": "observed approach"}]}, "sentence": " This methodology differs from the more observed approach used in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years.", "object": {"text": "in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years", "keywords": [{"text": "orthodox cytotoxic chemotherapy"}, {"text": "cancer treatment"}, {"text": "backbone"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "orthodox cytotoxic chemotherapy", "keywords": [{"text": "orthodox cytotoxic chemotherapy"}]}, "sentence": " This methodology differs from the more observed approach used in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years.", "object": {"text": "continued to be the backbone of cancer treatment over past several years", "keywords": [{"text": "cancer treatment"}, {"text": "backbone"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Kinase inhibitors therapy", "keywords": [{"text": "Kinase inhibitors"}, {"text": "therapy"}]}, "sentence": " Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.", "object": {"text": "the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy", "keywords": [{"text": "cytotoxic chemotherapy"}, {"text": "present difficulties"}, {"text": "possibility"}, {"text": "area"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Kinase inhibitors therapy", "keywords": [{"text": "Kinase inhibitors"}, {"text": "therapy"}]}, "sentence": " Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.", "object": {"text": "many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity", "keywords": [{"text": "cytotoxic chemotherapy"}, {"text": "present difficulties"}, {"text": "host-cell toxicity"}, {"text": "area"}]}, "action": {"verb": {"text": "eliminate", "tense": "future"}, "text": "to eliminate or reduce", "normalized": "to eliminate or reduce"}}, {"subject": {"text": "Kinase inhibitors therapy", "keywords": [{"text": "Kinase inhibitors"}, {"text": "therapy"}]}, "sentence": " Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.", "object": {"text": "many of the present difficulties in the area of cytotoxic chemotherapy", "keywords": [{"text": "cytotoxic chemotherapy"}, {"text": "present difficulties"}, {"text": "area"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "to eliminate or reduce", "normalized": "to eliminate or reduce"}}, {"subject": {"text": "Presently,kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "Presently,kinase inhibitors"}, {"text": "cancer treatmentglobal market"}]}, "sentence": " Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "object": {"text": "driven by some of the factors like technological progression", "keywords": [{"text": "technological progression"}, {"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease", "keywords": [{"text": "technological progression"}, {"text": "chronic disease"}, {"text": "healthcare area"}, {"text": "cancer patients"}]}, "sentence": " Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "object": {"text": "Presently,kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "Presently,kinase inhibitors"}, {"text": "cancer treatmentglobal market"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is driven", "normalized": "be drive"}}, {"subject": {"text": "Presently,kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "Presently,kinase inhibitors"}, {"text": "cancer treatmentglobal market"}]}, "sentence": " Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "object": {"text": "in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease", "keywords": [{"text": "chronic disease"}, {"text": "cancer patients"}, {"text": "prevalence"}, {"text": "incidence"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "high cost", "keywords": [{"text": "high cost"}]}, "sentence": " However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.", "object": {"text": "with latest clinical trials and complex approvals processes", "keywords": [{"text": "latest clinical trials"}, {"text": "complex approvals"}, {"text": "processes"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "high cost associated with latest clinical trials and complex approvals processes", "keywords": [{"text": "latest clinical trials"}, {"text": "complex approvals"}, {"text": "high cost"}, {"text": "processes"}]}, "sentence": " However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.", "object": {"text": "acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "kinase inhibitors"}, {"text": "major obstructions"}, {"text": "cancer treatmentglobal market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Kinase inhibitors for cancer treatment globalmarketis", "keywords": [{"text": "Kinase inhibitors"}, {"text": "cancer treatment globalmarketis"}]}, "sentence": " Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "object": {"text": "into following types", "keywords": [{"text": "types"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "segmented", "normalized": "segment"}}, {"subject": {"text": "cancer treatmentis", "keywords": [{"text": "cancer treatmentis"}]}, "sentence": " Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "object": {"text": "a healthy CAGR", "keywords": [{"text": "healthy CAGR"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "expected to register", "normalized": "expect to register"}}, {"subject": {"text": "healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients,", "keywords": [{"text": "healthy growth rate"}, {"text": "forecast period"}, {"text": "technological development"}, {"text": "upsurge"}]}, "sentence": " There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "object": {"text": "in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe", "keywords": [{"text": "adverse effects"}, {"text": "cancer patients"}, {"text": "chemotherapy"}, {"text": "prevalence"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "kinase inhibitors for cancer treatment market", "keywords": [{"text": "kinase inhibitors"}, {"text": "cancer treatment market"}]}, "sentence": " Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "object": {"text": "segmented into seven key regions", "keywords": [{"text": "key regions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "kinase inhibitors for cancer treatment market", "keywords": [{"text": "kinase inhibitors"}, {"text": "cancer treatment market"}]}, "sentence": " Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "object": {"text": "into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa", "keywords": [{"text": "Asia Pacific Excluding"}, {"text": "key regions"}, {"text": "North America"}, {"text": "Middle East"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "object": {"text": "for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients", "keywords": [{"text": "global kinase inhibitors"}, {"text": "largest market shares"}, {"text": "cancer treatment market"}, {"text": "geriatric population"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "accounts", "normalized": "account"}}, {"subject": {"text": "geriatric population", "keywords": [{"text": "geriatric population"}]}, "sentence": " In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "object": {"text": "with cancer indication.Whereas, North America and Asia-Pacific", "keywords": [{"text": "Asia-Pacific"}, {"text": "cancer indication.Whereas"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "North America and Asia-Pacific", "keywords": [{"text": "Asia-Pacific"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "action": {"verb": {"text": "project", "tense": "past"}, "text": "is projected showing", "normalized": "be project show"}}, {"subject": {"text": "kinase inhibitors for cancer treatmentin various regions", "keywords": [{"text": "kinase inhibitors"}, {"text": "treatmentin various regions"}, {"text": "cancer"}]}, "sentence": " Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "object": {"text": "particularly driven by gradually increasing awareness", "keywords": [{"text": "awareness"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment", "keywords": [{"text": "advanced technologies"}, {"text": "cancer patients"}, {"text": "cancer treatment"}, {"text": "incidence"}]}, "sentence": " Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "object": {"text": "kinase inhibitors for cancer treatmentin various regions", "keywords": [{"text": "kinase inhibitors"}, {"text": "treatmentin various regions"}, {"text": "cancer"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is particularly driven", "normalized": "be particularly drive"}}, {"subject": {"text": "Some of the key participating global players in kinase inhibitors for cancer treatment global market", "keywords": [{"text": "kinase inhibitors"}, {"text": "treatment global market"}, {"text": "global players"}, {"text": "cancer"}], "entities": []}, "sentence": " Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.", "object": {"text": "Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others", "keywords": [{"text": "Boehringer Ingelheim GmbH"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Novartis AG"}, {"text": "Incyte Corporation"}], "entities": [{"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Incyte Corporation", "disambiguation": {"subtype": [], "name": "Incyte", "dbpedia_resource": "http://dbpedia.org/resource/Incyte"}}, {"type": "Company", "text": "MedImmune", "disambiguation": {"subtype": ["Organization", "Company"], "name": "MedImmune", "dbpedia_resource": "http://dbpedia.org/resource/MedImmune"}}, {"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Cancer", "relevance": 0.986633, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Oncology", "relevance": 0.822186, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Chemotherapy", "relevance": 0.746128, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Tumor", "relevance": 0.579086, "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}, {"text": "United States", "relevance": 0.509826, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Europe", "relevance": 0.500866, "dbpedia_resource": "http://dbpedia.org/resource/Europe"}, {"text": "Boehringer Ingelheim", "relevance": 0.465216, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Immune system", "relevance": 0.461547, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Neoplasm", "relevance": 0.454492, "dbpedia_resource": "http://dbpedia.org/resource/Neoplasm"}, {"text": "Eastern Europe", "relevance": 0.428126, "dbpedia_resource": "http://dbpedia.org/resource/Eastern_Europe"}, {"text": "Adverse effect", "relevance": 0.413864, "dbpedia_resource": "http://dbpedia.org/resource/Adverse_effect"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.405835, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical industry", "relevance": 0.403472, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Epidemiology", "relevance": 0.401509, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Spain", "relevance": 0.388262, "dbpedia_resource": "http://dbpedia.org/resource/Spain"}, {"text": "Pharmacology", "relevance": 0.381964, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Ingelheim am Rhein", "relevance": 0.37493, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "North America", "relevance": 0.374434, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Cell cycle", "relevance": 0.364572, "dbpedia_resource": "http://dbpedia.org/resource/Cell_cycle"}, {"text": "Switzerland", "relevance": 0.362599, "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}, {"text": "Novartis", "relevance": 0.343418, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Americas", "relevance": 0.334646, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Western Europe", "relevance": 0.334501, "dbpedia_resource": "http://dbpedia.org/resource/Western_Europe"}, {"text": "Central Europe", "relevance": 0.322051, "dbpedia_resource": "http://dbpedia.org/resource/Central_Europe"}, {"text": "Cell", "relevance": 0.320264, "dbpedia_resource": "http://dbpedia.org/resource/Cell_(biology)"}, {"text": "Americas", "relevance": 0.319729, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Cell division", "relevance": 0.316351, "dbpedia_resource": "http://dbpedia.org/resource/Cell_division"}, {"text": "Breast cancer", "relevance": 0.314543, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Western world", "relevance": 0.307555, "dbpedia_resource": "http://dbpedia.org/resource/Western_world"}, {"text": "Inhibitor", "relevance": 0.306049, "dbpedia_resource": "http://dbpedia.org/resource/Inhibitor"}, {"text": "Clinical trial", "relevance": 0.305609, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Medicine", "relevance": 0.303295, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Medical statistics", "relevance": 0.302306, "dbpedia_resource": "http://dbpedia.org/resource/Medical_statistics"}, {"text": "Therapeutic effect", "relevance": 0.301071, "dbpedia_resource": "http://dbpedia.org/resource/Therapeutic_effect"}, {"text": "Pfizer", "relevance": 0.300414, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Latin America", "relevance": 0.296585, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Leukemia", "relevance": 0.296239, "dbpedia_resource": "http://dbpedia.org/resource/Leukemia"}, {"text": "Disease", "relevance": 0.296026, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "World War II", "relevance": 0.295678, "dbpedia_resource": "http://dbpedia.org/resource/World_War_II"}, {"text": "Russia", "relevance": 0.295502, "dbpedia_resource": "http://dbpedia.org/resource/Russia"}], "categories": [{"score": 0.728865, "label": "/health and fitness/disease/cancer"}, {"score": 0.386239, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.371515, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "Enhancedemphasis of pharmaceutical companies on R&D to come up with potential kinase inhibitors for treatment of cancers.", "score": 0.784774, "arguments": [{"text": "inhibitors", "location": [1518, 1528], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancers", "location": [1546, 1553], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "score": 0.644799, "arguments": [{"text": "inhibitors", "location": [1642, 1652], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [1657, 1663], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.", "score": 0.749969, "arguments": [{"text": "inhibitors", "location": [2026, 2036], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2041, 2047], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.857599, "arguments": [{"text": "inhibitors", "location": [2079, 2089], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2094, 2100], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.685265, "arguments": [{"text": "inhibitors", "location": [2522, 2532], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2537, 2543], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.705433, "arguments": [{"text": "inhibitors", "location": [2944, 2954], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2959, 2965], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.", "score": 0.749072, "arguments": [{"text": "inhibitors", "location": [3607, 3617], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [3622, 3628], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.576114, "arguments": [{"text": "inhibitors", "location": [3673, 3683], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [3688, 3694], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.", "score": 0.779677, "arguments": [{"text": "inhibitors", "location": [3931, 3941], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [3946, 3952], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.4926, "arguments": [{"text": "regions", "location": [3011, 3018], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Western Europe", "location": [3066, 3080], "entities": [{"type": "GeopoliticalEntity", "text": "Western Europe"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.518745, "arguments": [{"text": "Asia", "location": [3082, 3086], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3087, 3094], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "score": 0.872703, "arguments": [{"text": "region", "location": [3156, 3162], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [3163, 3169], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "score": 0.829177, "arguments": [{"text": "population", "location": [3343, 3353], "entities": [{"type": "Person", "text": "population"}]}, {"text": "cancer indication.Whereas", "location": [3359, 3384], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "residesIn", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.473014, "arguments": [{"text": "inhibitors", "location": [3673, 3683], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "regions", "location": [3715, 3722], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.549751, "arguments": [{"text": "patients", "location": [3808, 3816], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "regions", "location": [3715, 3722], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "hasAttribute", "sentence": "Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "score": 0.812563, "arguments": [{"text": "patients", "location": [1804, 1812], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [1797, 1803], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "score": 0.902903, "arguments": [{"text": "patients", "location": [2769, 2777], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [2762, 2768], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "score": 0.82648, "arguments": [{"text": "patients", "location": [2877, 2885], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [2870, 2876], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "score": 0.847158, "arguments": [{"text": "patients", "location": [3546, 3554], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [3539, 3545], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.89156, "arguments": [{"text": "patients", "location": [3808, 3816], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [3801, 3807], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "employedBy", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.634289, "arguments": [{"text": "inhibitors", "location": [2231, 2241], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "MEK", "location": [2227, 2230], "entities": [{"type": "Organization", "text": "MEK"}]}]}, {"type": "employedBy", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.531704, "arguments": [{"text": "inhibitors", "location": [2290, 2300], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "EGFR", "location": [2285, 2289], "entities": [{"type": "Organization", "text": "EGFR"}]}]}, {"type": "locatedAt", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.526167, "arguments": [{"text": "Latin America", "location": [2429, 2442], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}, {"text": "Western Europe", "location": [2444, 2458], "entities": [{"type": "GeopoliticalEntity", "text": "Western Europe"}]}]}, {"type": "locatedAt", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.857623, "arguments": [{"text": "APEJ", "location": [2476, 2480], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}, {"text": "Japan", "location": [2482, 2487], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "score": 0.811686, "arguments": [{"text": "patients", "location": [2877, 2885], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "globe", "location": [2897, 2902], "entities": [{"type": "GeographicFeature", "text": "globe"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.539305, "arguments": [{"text": "regions", "location": [3011, 3018], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [3035, 3048], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.621212, "arguments": [{"text": "regions", "location": [3011, 3018], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Eastern Europe", "location": [3050, 3064], "entities": [{"type": "GeopoliticalEntity", "text": "Eastern Europe"}]}]}], "keywords": [{"text": "kinase inhibitors", "sentiment": {"score": -0.40248, "label": "negative"}, "relevance": 0.902143}, {"text": "kinase inhibitors therapy", "sentiment": {"score": -0.509676, "label": "negative"}, "relevance": 0.770664}, {"text": "cancer treatment", "sentiment": {"score": -0.376333, "label": "negative"}, "relevance": 0.697065}, {"text": "global kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.696982}, {"text": "potential kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.692497}, {"text": "Type- Angiogenesis inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587537}, {"text": "Bcr-Abl tyrosine-kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586397}, {"text": "kinase inhibitor treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58614}, {"text": "kinase inhibitor therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583737}, {"text": "Presently,kinase inhibitors", "sentiment": {"score": -0.63858, "label": "negative"}, "relevance": 0.559444}, {"text": "MEK inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558442}, {"text": "m-TOR inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55544}, {"text": "EGFR inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555035}, {"text": "PI3K Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554901}, {"text": "aurora-kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55482}, {"text": "cancer treatmentglobal market", "sentiment": {"score": -0.579016, "label": "negative"}, "relevance": 0.551781}, {"text": "cancer patients", "sentiment": {"score": -0.678874, "label": "negative"}, "relevance": 0.551633}, {"text": "cancer treatment market", "sentiment": {"score": -0.255387, "label": "negative"}, "relevance": 0.54854}, {"text": "forecast period", "sentiment": {"score": 0.179933, "label": "positive"}, "relevance": 0.510989}, {"text": "North America", "sentiment": {"score": -0.216194, "label": "negative"}, "relevance": 0.505934}, {"text": "cancer treatment globalmarketis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504514}, {"text": "cytotoxic chemotherapy", "sentiment": {"score": -0.687333, "label": "negative"}, "relevance": 0.493354}, {"text": "treatment global market", "sentiment": {"score": -0.361238, "label": "negative"}, "relevance": 0.491509}, {"text": "orthodox cytotoxic chemotherapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.490496}, {"text": "therapeutic index", "sentiment": {"score": -0.282746, "label": "negative"}, "relevance": 0.478625}, {"text": "largest market shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473578}, {"text": "minimum adverse effect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47247}, {"text": "Boehringer Ingelheim GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472178}, {"text": "wider therapeutic index", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472141}, {"text": "clinical trials", "sentiment": {"score": -0.395171, "label": "negative"}, "relevance": 0.471985}, {"text": "particular molecular target", "sentiment": {"score": -0.33202, "label": "negative"}, "relevance": 0.471513}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470928}, {"text": "Western Europe", "sentiment": {"score": 0.265379, "label": "positive"}, "relevance": 0.470872}, {"text": "Eastern Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470871}, {"text": "healthy growth rate", "sentiment": {"score": 0.423137, "label": "positive"}, "relevance": 0.469835}, {"text": "complex approvals processes", "sentiment": {"score": -0.519452, "label": "negative"}, "relevance": 0.46935}, {"text": "latest clinical trials", "sentiment": {"score": -0.519452, "label": "negative"}, "relevance": 0.469328}, {"text": "healthy CAGR", "sentiment": {"score": -0.243203, "label": "negative"}, "relevance": 0.469082}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": -0.239557, "label": "negative"}, "relevance": 0.467772}, {"text": "Pacific Excluding Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.46721}, {"text": "Request Report Sample", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.465909}, {"text": "treatmentin various regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464139}, {"text": "cancer molecules", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464128}, {"text": "cancer treatmentis", "sentiment": {"score": -0.270212, "label": "negative"}, "relevance": 0.458972}, {"text": "cancer indication.Whereas", "sentiment": {"score": -0.367127, "label": "negative"}, "relevance": 0.456663}, {"text": "cancer treatmentmarket", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.455951}, {"text": "anticancer treatment", "sentiment": {"score": -0.33202, "label": "negative"}, "relevance": 0.455437}, {"text": "cell division", "sentiment": {"score": -0.39172, "label": "negative"}, "relevance": 0.444377}, {"text": "cancerous cells", "sentiment": {"score": -0.39172, "label": "negative"}, "relevance": 0.444233}, {"text": "specific enzymes", "sentiment": {"score": -0.39172, "label": "negative"}, "relevance": 0.443517}]}, "extracted_metadata": {"sha1": "c973d507c57f04480bb2c9f50466afc3dc621089", "filename": "1541171720354.zip-d82abcc52852bf4095bad100173fd6cf.xml", "file_type": "json"}, "external_links": ["http://www.futuremarketinsights.com/reports/sample/rep-gb-1403", "http://www.futuremarketinsights.com/reports/kinase-inhibitors-for-cancer-treatment-market"], "title": "Kinase Inhibitors For Cancer Treatment Market Detailed Analytical Overview by 2026", "forum_title": "Automotive &amp; Transportation \u2013 Page 4 \u2013 Find Market Research"}, {"id": "UzciUomMr8awdycvFXjQQ89mFeqODy4Hy3Fy9WxRPnFcfBrywxMFjmnbr3n9WriF", "result_metadata": {"score": 32.492943}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.32966, "label": "negative"}, "text": "Shire Pharmaceuticals Group Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.296837, "label": "positive"}, "text": "The Vanguard Group", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "The Vanguard Group", "dbpedia_resource": "http://dbpedia.org/resource/The_Vanguard_Group"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Shire Pharmaceuticals Group Ltd", "keywords": [{"text": "Pharmaceuticals Group"}], "entities": [{"type": "Company", "text": "Shire Pharmaceuticals Group Ltd"}]}, "sentence": "Shire Pharmaceuticals Group Ltd (JE00B2QKY057) : Form 8.3 - The Vanguard Group, Inc.: Shire plc", "action": {"verb": {"text": "Form", "tense": "present"}, "text": "Form", "normalized": "Form"}}], "concepts": [], "categories": [{"score": 0.525488, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.516065, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.458515, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Shire Pharmaceuticals Group", "sentiment": {"score": -0.32966, "label": "negative"}, "relevance": 0.916723}, {"text": "Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629597}, {"text": "Vanguard Group", "sentiment": {"score": 0.296837, "label": "positive"}, "relevance": 0.421473}]}, "crawl_date": "2018-11-02T15:34:09Z", "url": "http://lesechos-comfi.lesechos.fr/actualite.html?id=819541", "host": "lesechos-comfi.lesechos.fr", "text": "If it is a cash offer or possible cash offer , state \"N /A \" Yes, Takeda Pharmaceutical Company Limited 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T15:27:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.996573, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.898617, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.78799, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.720693, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.317463, "label": "positive"}, "text": "The Vanguard Group, Inc.", "relevance": 0.693683, "type": "Company"}], "sentiment": {"document": {"score": -0.315458, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "he"}, "sentence": "(a) Full name of discloser : The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): T he naming of nominee or vehicle companies is insufficient .", "object": {"text": "T"}, "action": {"verb": {"text": "name", "tense": "present"}, "text": "naming", "normalized": "name"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer , state \"N /A \" Yes, Takeda Pharmaceutical Company Limited 2.", "object": {"text": "a cash offer or possible cash offer , state \"N /A \" Yes, Takeda Pharmaceutical Company Limited 2", "keywords": [{"text": "possible cash offer"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "state"}, {"text": "/A"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant sec urities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.920188, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Offer and acceptance", "relevance": 0.901341, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "The Vanguard Group", "relevance": 0.900802, "dbpedia_resource": "http://dbpedia.org/resource/The_Vanguard_Group"}, {"text": "Uniform Commercial Code", "relevance": 0.749843, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}], "categories": [{"score": 0.570178, "label": "/real estate/buying and selling homes"}, {"score": 0.47496, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.454542, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.94356}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.861577}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.785595}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.75508}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.749609}, {"text": "test practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.74495}, {"text": "possible cash offer", "sentiment": {"score": 0.408536, "label": "positive"}, "relevance": 0.735127}, {"text": "Vanguard Group", "sentiment": {"score": 0.317463, "label": "positive"}, "relevance": 0.562737}, {"text": "vehicle companies", "sentiment": {"score": -0.451797, "label": "negative"}, "relevance": 0.541385}, {"text": "Novem ber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535479}, {"text": "offeror/offeree Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510444}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508748}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503204}, {"text": "relevant sec", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.490858}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471217}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467978}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333988}, {"text": "discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.305857}, {"text": "interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303179}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.287482}, {"text": "nominee", "sentiment": {"score": -0.451797, "label": "negative"}, "relevance": 0.285132}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.28331}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280491}, {"text": "controller", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.268174}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257848}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257664}, {"text": "Owner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257564}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256681}, {"text": "trust", "sentiment": {"score": 0.575723, "label": "positive"}, "relevance": 0.253618}, {"text": "settlor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253428}, {"text": "identity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250835}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249498}, {"text": "/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248215}, {"text": "Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248056}]}, "extracted_metadata": {"sha1": "651652eb5c7c9023a5980fb805e41b4445a0584d", "filename": "1541172849770.zip-5aa7ca6297abd43233c75f7d83c2b060.xml", "file_type": "json"}, "external_links": ["http://www.facebook.com/2008/fbml"], "title": "Shire Pharmaceuticals Group Ltd (JE00B2QKY057) : Form 8.3 - The Vanguard Group, Inc.: Shire plc", "forum_title": "Webdisclosure.com - Financial Communication"}, {"id": "Fe6k4503lk5my3kdk3EFfNdfLiW8HlchCQhyec6XtbQIQu4Zau_-9JkjbjBeRrie", "result_metadata": {"score": 32.19262}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.504344, "label": "/finance/investing/brokerages"}, {"score": 0.502277, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.49338, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995973}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.917124}, {"text": "UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.834559}]}, "crawl_date": "2018-11-03T07:06:51Z", "url": "https://www.businesswire.com/news/home/20181102005158/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T07:00:00-05:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.718387, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.631737, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.613015, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.565582, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.545837, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.527506, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.502351, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.497555, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.490382, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.490382, "type": "Quantity"}], "sentiment": {"document": {"score": -0.261081, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "1 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 1 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 658678 Time of Receipt (offset from UTC): 20181102T060033+0000 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.967727, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.499243, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Offer and acceptance", "relevance": 0.493331, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Strike price", "relevance": 0.482643, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.448577, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.406235, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.398783, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.390904, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.389829, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Security", "relevance": 0.379896, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Balance sheet", "relevance": 0.378414, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Option contract", "relevance": 0.377055, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Stock", "relevance": 0.361504, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Legal person", "relevance": 0.3551, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}], "categories": [{"score": 0.706935, "label": "/real estate/buying and selling homes"}, {"score": 0.485953, "label": "/finance/financial news"}, {"score": 0.304842, "label": "/finance/investing/day trading"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 1 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [700, 707], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [626, 663], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4557, 4563], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4574, 4581], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 2 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5392, 5404], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5406, 5435], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 2 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5495, 5501], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5509, 5513], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5576, 5600], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5568, 5573], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5855, 5879], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5847, 5852], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5911, 5916], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5930, 5957], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 658678 Time of Receipt (offset from UTC): 20181102T060033+0000 Contacts Daiwa Asset Management", "score": 0.488667, "arguments": [{"text": "UTC", "location": [6067, 6070], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [6046, 6053], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "JPY ORD Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.965802}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.898195}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.789545}, {"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.696871}, {"text": "JPY ORD Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680407}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.617863}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610669}, {"text": "short positions", "sentiment": {"score": -0.356746, "label": "negative"}, "relevance": 0.545732}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5023}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.480799}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459745}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.450498}, {"text": "reference securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450065}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443804}, {"text": "Short positions Number", "sentiment": {"score": -0.245708, "label": "negative"}, "relevance": 0.436482}, {"text": "relevant security Purchase/sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436093}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.435144}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.430597}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429223}, {"text": "Asset Management Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.428272}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424609}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422609}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420945}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420158}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420142}, {"text": "derivative transactions", "sentiment": {"score": -0.408268, "label": "negative"}, "relevance": 0.419877}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419803}, {"text": "Contacts Daiwa Asset", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415132}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.415059}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.414501}, {"text": "Cash-settled derivative transactions", "sentiment": {"score": -0.403941, "label": "negative"}, "relevance": 0.411103}, {"text": "Expiry date Option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411012}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.410202}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409729}, {"text": "unit Type e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408176}, {"text": "RET Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406242}, {"text": "Asset Management Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405277}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405051}, {"text": "Product description e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403315}, {"text": "long/short position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.402977}, {"text": "Management Category Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40293}, {"text": "person", "sentiment": {"score": 0.217529, "label": "positive"}, "relevance": 0.397845}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.397605}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.394633}, {"text": "Nil", "sentiment": {"score": -0.611983, "label": "negative"}, "relevance": 0.388571}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384973}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381838}, {"text": "LONDON-\nFORM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374744}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373569}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372684}]}, "extracted_metadata": {"sha1": "4ab48949027ea5a3e23b2af954082ff2c126311b", "filename": "1541228811359.zip-1ad442880f2fcf34480c17936e04f204.xml", "file_type": "json"}, "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}, {"id": "YWE87gMsdRE-7UmeVudGnBH8kBoCLGJ5Wr5CBkw62VXVZnZk9iMDTAn25vtj94QD", "result_metadata": {"score": 31.393322}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.751332, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.960106}, {"text": "Barclays", "sentiment": {"score": 0.328886, "label": "positive"}, "relevance": 0.796292}]}, "crawl_date": "2018-11-02T15:24:05Z", "url": "http://www.4-traders.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-27535015/", "host": "4-traders.com", "text": "Name of offeror/offeree in relation to whose relevant securities the disclosure relates: TAKEDA PHARMACEUTICAL CO LTD 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T00:00:00+01:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC", "relevance": 0.935831, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.558812, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.497963, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.483333, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.479702, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.430803, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.428133, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.407187, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.400763, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.393862, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.393862, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,054,064 1.39%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,747,886 1.48%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,137,779 1.53%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,323,550 4.19%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,334,679 4.19%", "relevance": 0.393862, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.393862, "type": "Quantity"}], "sentiment": {"document": {"score": 0.124658, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state 'N/A'", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,323,550 4.19% 33,334,679 4.19% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "33,323,550 4.19"}, {"type": "Quantity", "text": "33,334,679 4.19"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,054,064 1.39% 12,137,779 1.53% (2) Cash-settled derivatives: 11,747,886 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,323,550 4.19% 33,334,679 4.19% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,323,550 4.19% 33,334,679 4.19% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,323,550 4.19"}, {"type": "Quantity", "text": "33,334,679 4.19"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,054,064 1.39% 12,137,779 1.53% (2) Cash-settled derivatives: 11,747,886 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,323,550 4.19% 33,334,679 4.19% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "person", "keywords": [{"text": "person"}]}, "sentence": " Full name of person making disclosure: Barclays PLC.", "object": {"text": "disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "Barclays PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 02 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 02 November 2018 14:42:15 UTC", "object": {"text": "15 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.972742, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.736311, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.688479, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.611053, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.501364, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.408162, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.3966, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.376849, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.344102, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.330347, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Bond", "relevance": 0.320919, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Barclays", "relevance": 0.311952, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Contract", "relevance": 0.307726, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Unit type", "relevance": 0.299486, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United Kingdom company law", "relevance": 0.290919, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom_company_law"}], "categories": [{"score": 0.597517, "label": "/real estate/buying and selling homes"}, {"score": 0.462276, "label": "/finance/financial news"}, {"score": 0.439314, "label": "/finance/investing"}], "relations": [{"type": "employedBy", "sentence": "JPY Ordinary NPV Sale 34,600 4,657.7774 JPY Ordinary NPV Sale 80,200 4,644.7693 JPY Ordinary NPV Sale 220,500 4,642.4217 JPY Ordinary NPV Sale 458,700 4,633.5515 JPY Ordinary NPV Sale 461,700 4,633.8453 JPY Ordinary NPV Sale 531,000 4,624.5967 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 100 4,639.0000 JPY Ordinary NPV CFD Long 20,000 4,587.0000 JPY Ordinary NPV SWAP Short 166,500 4,587.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.500498, "arguments": [{"text": "Cash", "location": [5161, 5165], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [5207, 5221], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005367/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 02 November 2018 and is solely responsible for the information contained herein.", "score": 0.990154, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10421, 10454], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10455, 10464], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005367/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 02 November 2018 and is solely responsible for the information contained herein.", "score": 0.648658, "arguments": [{"text": "November 2018", "location": [10484, 10497], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10455, 10464], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 34,600 4,657.7774 JPY Ordinary NPV Sale 80,200 4,644.7693 JPY Ordinary NPV Sale 220,500 4,642.4217 JPY Ordinary NPV Sale 458,700 4,633.5515 JPY Ordinary NPV Sale 461,700 4,633.8453 JPY Ordinary NPV Sale 531,000 4,624.5967 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 100 4,639.0000 JPY Ordinary NPV CFD Long 20,000 4,587.0000 JPY Ordinary NPV SWAP Short 166,500 4,587.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.657678, "arguments": [{"text": "i", "location": [5505, 5506], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Purchase"}]}, {"text": "Writing", "location": [5508, 5515], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [6105, 6110], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [6115, 6119], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6479, 6485], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6496, 6503], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 2 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "score": 0.756243, "arguments": [{"text": "Rule 8", "location": [7404, 7410], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7418, 7422], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7929, 7935], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7943, 7956], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7564, 7588], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7556, 7561], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10050, 10074], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10042, 10047], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7723, 7728], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7742, 7769], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10209, 10214], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10228, 10255], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 0 Jan 1900 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9544, 9545], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9535, 9543], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 0 Jan 1900 3.", "score": 0.406878, "arguments": [{"text": "0", "location": [9695, 9696], "entities": [{"type": "Person", "text": "0"}]}, {"text": "European", "location": [9686, 9694], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.947177}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.762707}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.693944}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422276}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420094}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.417363}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41671}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.415841}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411823}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.375436}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.360714}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348428}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332428}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315079}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.288476}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279007}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.274256}, {"text": "barclays plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271414}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2693}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26513}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.258743}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257876}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2562}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256121}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.255573}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.255194}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254861}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244246}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240269}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239201}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.239004}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.238829}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.238779}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23795}, {"text": "disclosure requirements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23792}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237597}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237418}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23672}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235905}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23574}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235715}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235711}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235483}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235176}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235081}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234975}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.234762}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233662}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233288}, {"text": "derivative transactions Class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233218}]}, "extracted_metadata": {"sha1": "5043adc88683bf8c417275fe6a947c7126a8f513", "filename": "1541172245280.zip-0c23b61db8c3969ccf3c4d8be5c85d4e.xml", "file_type": "json"}, "external_links": ["http://www.publicnow.com/view/2D6E08FEAD4F1B691DC0C7D370643F3F236AE0C3", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1204825", "https://www.businesswire.com/news/home/20181102005367/en/"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "F100 Stock Quote | FTSE 100 Index Stock Price () | Autre: F100 | MarketScreener"}, {"id": "ORA2R5bdPfBtE6pv4Q5LGEQqQjT7MoH8WQhoIw9ZqrpMuBVgiHuKIaVVcqBoFH_j", "result_metadata": {"score": 30.808868}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-02T18:51:24Z", "url": "https://www.businesswire.com/news/home/20181102005367/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "Name of offeror/offeree in relation to whose relevant securities the disclosure relates: TAKEDA PHARMACEUTICAL CO LTD 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T14:32:00-05:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC", "relevance": 0.82871, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.629921, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.526974, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.519767, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.501114, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.477632, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.464674, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.461656, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.442947, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.433304, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.425848, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.425848, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,054,064 1.39%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,747,886 1.48%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,137,779 1.53%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,323,550 4.19%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,334,679 4.19%", "relevance": 0.425848, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.425848, "type": "Quantity"}], "sentiment": {"document": {"score": 0.083948, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,323,550 4.19% 33,334,679 4.19% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "33,323,550 4.19"}, {"type": "Quantity", "text": "33,334,679 4.19"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,054,064 1.39% 12,137,779 1.53% (2) Cash-settled derivatives: 11,747,886 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,323,550 4.19% 33,334,679 4.19% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,323,550 4.19% 33,334,679 4.19% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,323,550 4.19"}, {"type": "Quantity", "text": "33,334,679 4.19"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,054,064 1.39% 12,137,779 1.53% (2) Cash-settled derivatives: 11,747,886 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,323,550 4.19% 33,334,679 4.19% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "person", "keywords": [{"text": "person"}]}, "sentence": " Full name of person making disclosure: Barclays PLC.", "object": {"text": "disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658727 Time of Receipt (offset from UTC): 20181102T140734+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.976953, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.738605, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.695321, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.619148, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.505225, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.410256, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.403693, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378389, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.347411, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.330799, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Bond", "relevance": 0.324168, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Contract", "relevance": 0.312974, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Unit type", "relevance": 0.302109, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.29498, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.602997, "label": "/real estate/buying and selling homes"}, {"score": 0.452442, "label": "/finance/financial news"}, {"score": 0.443453, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 0 Jan 1900 3.", "score": 0.406878, "arguments": [{"text": "0", "location": [9677, 9678], "entities": [{"type": "Person", "text": "0"}]}, {"text": "European", "location": [9668, 9676], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658727 Time of Receipt (offset from UTC): 20181102T140734+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [10337, 10340], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10316, 10323], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "employedBy", "sentence": "JPY Ordinary NPV Sale 34,600 4,657.7774 JPY Ordinary NPV Sale 80,200 4,644.7693 JPY Ordinary NPV Sale 220,500 4,642.4217 JPY Ordinary NPV Sale 458,700 4,633.5515 JPY Ordinary NPV Sale 461,700 4,633.8453 JPY Ordinary NPV Sale 531,000 4,624.5967 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 100 4,639.0000 JPY Ordinary NPV CFD Long 20,000 4,587.0000 JPY Ordinary NPV SWAP Short 166,500 4,587.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.500498, "arguments": [{"text": "Cash", "location": [5143, 5147], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [5189, 5203], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 34,600 4,657.7774 JPY Ordinary NPV Sale 80,200 4,644.7693 JPY Ordinary NPV Sale 220,500 4,642.4217 JPY Ordinary NPV Sale 458,700 4,633.5515 JPY Ordinary NPV Sale 461,700 4,633.8453 JPY Ordinary NPV Sale 531,000 4,624.5967 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 100 4,639.0000 JPY Ordinary NPV CFD Long 20,000 4,587.0000 JPY Ordinary NPV SWAP Short 166,500 4,587.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.657678, "arguments": [{"text": "i", "location": [5487, 5488], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Purchase"}]}, {"text": "Writing", "location": [5490, 5497], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [6087, 6092], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [6097, 6101], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6461, 6467], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6478, 6485], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 2 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.", "score": 0.756243, "arguments": [{"text": "Rule 8", "location": [7386, 7392], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7400, 7404], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7911, 7917], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7925, 7938], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7546, 7570], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7538, 7543], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10032, 10056], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10024, 10029], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7705, 7710], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7724, 7751], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10191, 10196], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10210, 10237], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 0 Jan 1900 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9526, 9527], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9517, 9525], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.949585}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.764927}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.696256}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426226}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423303}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420926}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420229}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.415998}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415154}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.385169}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369805}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350718}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338391}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315129}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279227}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270718}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.268727}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.268475}, {"text": "barclays plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265536}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264205}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262395}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261858}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261017}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260582}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259974}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256476}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.255285}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244639}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24111}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240535}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239605}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.239052}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.238932}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23839}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237942}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23782}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23684}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236546}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.236265}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236032}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235879}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235864}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235829}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235596}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235262}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235198}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.235044}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234108}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234081}, {"text": "date relevant selling", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233872}]}, "extracted_metadata": {"sha1": "038a1ffee9c8d61a566936696d753cff7dd91a4c", "filename": "1541184684406.zip-6e3d76f06244e2a2aa4e5f0984cad38f.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "s3V_7dJkkOslt-kxgwOXswQOp0uWOM-s-vrpcmeAnQUXxxS7FVoSfnflh1MoDygF", "result_metadata": {"score": 27.938425}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.649241, "label": "/finance/bank"}, {"score": 0.440128, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.407319, "label": "/finance/bank/atms"}], "relations": [], "keywords": [{"text": "Norges Bank", "sentiment": {"score": -0.230595, "label": "negative"}, "relevance": 0.966282}, {"text": "Shire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.954249}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339222}]}, "crawl_date": "2018-11-02T15:40:26Z", "url": "http://www.4-traders.com/SHIRE-PLC-10825/news/Norges-Bank-Form-8-3-Shire-PLC-27535216/", "host": "4-traders.com", "text": "If it is a cash offer or possible cash offer, state \u201cN/A\u201d Yes Takeda Pharmaceutical Co Ltd 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T00:00:00+01:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.607202, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.553593, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.535992, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.531437, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.518005, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501265, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.492202, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.466042, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.466042, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.466042, "type": "Quantity"}], "sentiment": {"document": {"score": -0.0157859, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Shire PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Shire PLC", "keywords": [{"text": "offeror/offeree Shire PLC"}], "entities": [{"type": "Company", "text": "Shire PLC", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Shire PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Shire PLC (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Shire PLC"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Shire PLC", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Shire PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree: N/A (e) Date position held/dealing", "keywords": [{"text": "Date position held/dealing"}, {"text": "N/A"}, {"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "01/11/2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 01/11/2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d Yes", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " Class of relevant security: 5p ordinary & ADR's Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 23,265,455 2.54 (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "23,265,455 2.54 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " TOTAL: 23,265,455 2.54 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 02/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 02/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "+4724073297 Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Date of disclosure: 02/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.973602, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.538169, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.518423, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.514025, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.463437, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.434274, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.41823, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.407011, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.383486, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Unit type", "relevance": 0.372208, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.369669, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Security", "relevance": 0.36286, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Security", "relevance": 0.355436, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.35479, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Derivative", "relevance": 0.352055, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.338894, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.726789, "label": "/real estate/buying and selling homes"}, {"score": 0.494561, "label": "/finance/financial news"}, {"score": 0.277553, "label": "/finance/investing/day trading"}], "relations": [{"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit 5p ordinary Purchase 45,377 GBP 46.2563 5p ordinary Purchase 83,971 GBP 46.3033 ADR Purchase 5,500 USD 180.1103 ADR Purchase 55,000 USD 180.1103 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.726237, "arguments": [{"text": "i", "location": [3249, 3250], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3252, 3259], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3849, 3854], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3859, 3863], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4223, 4229], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4240, 4247], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 02/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5118, 5124], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5132, 5136], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5279, 5303], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5271, 5276], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5438, 5443], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5457, 5484], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.398424, "label": "positive"}, "relevance": 0.954628}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.829701}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.650844}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641644}, {"text": "disclosure Dealing Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557573}, {"text": "short positions", "sentiment": {"score": -0.293925, "label": "negative"}, "relevance": 0.500203}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.491775}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.474118}, {"text": "reference securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474091}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467386}, {"text": "relevant security Purchase/sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450634}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.450564}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.446526}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443294}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.439776}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436662}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434137}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43231}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43134}, {"text": "long/short position Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42982}, {"text": "offeror/offeree Shire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427258}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.426603}, {"text": "possible cash offer", "sentiment": {"score": 0.410812, "label": "positive"}, "relevance": 0.426391}, {"text": "Expiry date Option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425796}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.408511, "label": "negative"}, "relevance": 0.424424}, {"text": "Chiaroni Telephone number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419588}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419512}, {"text": "conversion Details Price", "sentiment": {"score": 0.287349, "label": "positive"}, "relevance": 0.418529}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416175}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414523}, {"text": "ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411671}, {"text": "ordinary Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409434}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.404135}, {"text": "person", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.403872}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.391007}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381837}, {"text": "Norges Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379431}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37887}, {"text": "Number % Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377789}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374945}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374497}, {"text": "vehicle companies", "sentiment": {"score": -0.671605, "label": "negative"}, "relevance": 0.37327}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371105}, {"text": "Interests Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370596}, {"text": "employee options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369527}, {"text": "e.g. American", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.36941}, {"text": "option arrangement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368855}, {"text": "Stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368455}, {"text": "Cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368156}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367839}]}, "extracted_metadata": {"sha1": "fc26c1a20fbd6ff1f2029b980116d16c6b75a6ea", "filename": "1541173226163.zip-8a4e6380ca96b476ea00065cda221111.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "Norges Bank : - Form 8.3 - Shire PLC", "forum_title": "Markets : News, Latest News - Marketscreener.com"}]}